BioForce Nanosciences Announces Sale of Nano eNabler System to Georgia Institute of Technology
AMES, Iowa, Nov. 28, 2007 -- (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings Inc. (OTC BB: BFNH) announced today the sale of a Nano eNabler™ molecular printing system to the Georgia Institute of Technology.
The Nano eNabler system is a platform for merging biology with nanotechnology. Researchers use this system for constructing ultraminiaturized biosensors and molecular diagnostic tests to create smaller and more effective diagnostic tests, as well as improved therapeutics. Additionally, areas such as cancer cell biology, stem cell biology and tissue engineering benefit from the Nano eNabler’s ability to create ultraminiaturized living test environments for research at the single-cell level.
BioForce’s President and COO, Kerry Frey, said, “The sale to Georgia Tech resulted from our market-seeding Pilot Placement Program, which was initiated in 2006. Under this program, we identified 20 prestigious biomedical and life sciences research institutions and allowed researchers at those sites to have access to this new technology for a defined period of time. Our goal was to conclude this test period with a sale. Georgia Tech is an example of a placement site that recognized the value of the Nano eNabler in their research and purchased it to continue their cutting-edge research. The placement program has created significant awareness within the biomedical and life sciences research communities of the Nano eNabler’s capabilities, leading to conversion to sale for placement sites, as well as sales to new Nano eNabler sites.”
Describing the research at Georgia Tech, Dr. Curtis Mosher, BioForce’s vice president of R&D said, “The Microelectronics Research Center on the Georgia Tech campus is a prime example of a core facility seeking to provide its users access to the latest technology. Pilot program users of the facility have employed the Nano eNabler system for placing polymers on diagnostic sensors in highly precise patterns. Sensors like this can lead to a new generation of diagnostic and sensing devices for environmental monitoring, remote chemical analysis and personalized medicine. It’s exciting to see advances like this being made possible by our technology.”
BioForce’s Nano eNabler™ system Product Manager, Michael Lynch, added, “We have a comprehensive customer care program that is a critical component of our customer enabling product and service offering. This client-focused approach has resulted in a group of enthusiastic Nano eNabler™ system users who are helping us rapidly expand awareness of the system’s capabilities in the academic and industrial research communities.”
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNablerTM molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization, patterning and cell adhesion, and printing proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
Contact:
BioForce Nanosciences Holdings, Inc.
Greg Brown, CFO
515-233-8333 ext. 118
gbrown@bioforcenano.com
RedChip Companies, Inc.
Investor Relations
Dave Gentry
1-800-REDCHIP (733-2447) ext. 104
dave@redchip.com
www.redchip.com
Wednesday, November 28, 2007
Cutting-Edge Healthcare Company Awarded For its Sample Prep. Technology
Frost & Sullivan Lauds Pressure BioSciences' Novel and Systematic Approach for the Detergent-free Extraction and Fractionation of Proteins from Lipid-rich Samples
Tuesday November 27, 11:22 am ET
PALO ALTO, Calif.--(BUSINESS WIRE)--Based on its recent analysis of the protein separation technologies market, Frost & Sullivan today announced that Pressure BioSciences, Inc. (NasdaqCM: PBIO) has been named the recipient of the 2007 North American Frost & Sullivan Award for Technology Innovation.
This Award recognizes Pressure BioSciences for its development of a new, cutting-edge sample preparation technology for tissue and cell disruption and for the development of a method for the detergent-free extraction of proteins from lipid rich tissues. This novel approach combines the power of the Company?s Pressure Cycling Technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.
?Protein expression from lipid rich tissues is crucial to understanding many disease states such as obesity, heart disease, diabetes, and certain cancer types, among others,? says Frost & Sullivan Senior Research Analyst Sandhya Kamath. ?As a result, sample preparation is drawing attention in proteomic studies since it can affect the accuracy and the overall quality of the downstream analytical processes.?
For instance, conventional detergent-based methods used to extract proteins from tissues produce highly variable results. This increases the processing time for protein extraction as well as the costs, compromising the quantity and quality of the extracted proteins.
Pressure BioSciences offers an automated method of protein extraction that allows for optimal protein recovery.
?Unlike conventional methods of tissue delipidation that comprise several stages such as cell and tissue disruption, protein extraction from lipids, and partitioning, the new PCT-dependent sample preparation approach from Pressure BioSciences combines these complex stages into a single step, as a result of which the fractions of proteins and lipids generated from each sample can be analyzed individually, faster, more efficiently, and with more reproducibility,? notes Kamath. ?Moreover, this approach integrates PCT and reagents to extract and fractionate proteins from lipid-rich tissues in a detergent-free manner.?
Pressure BioSciences? PCT technology can be applied across genomic and proteomic sample preparation, enzyme control, pathogen inactivation, immunodiagnostics, and protein purification.
To enhance the proof of concept, scientists at Pressure BioSciences collaborated with researchers at the Harvard School of Public Health to carry out a research study on the comparative proteomic analysis of adipose tissue isolated from genetically different animal lines.
The study exposed differences in protein expression that could be the base for newer research in mechanistic studies of obesity and Type 2 diabetes. The firm?s researchers are also working to widen the scope of pressure-driven liquid-liquid extraction in biological samples.
In recognition of Pressure BioSciences? commendable innovation and the resulting technology advancement in the extraction and fractionation of proteins, Frost & Sullivan proudly presents it with the 2007 Award for Technology Innovation.
Each year, Frost & Sullivan presents this Award to the company that has demonstrated excellence in new products and technologies within their industry. The Award recognizes innovation through the launch of a broad line of emerging products and technologies.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Pressure BioSciences
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information, visit http://www.awards.frost.com.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday November 27, 11:22 am ET
PALO ALTO, Calif.--(BUSINESS WIRE)--Based on its recent analysis of the protein separation technologies market, Frost & Sullivan today announced that Pressure BioSciences, Inc. (NasdaqCM: PBIO) has been named the recipient of the 2007 North American Frost & Sullivan Award for Technology Innovation.
This Award recognizes Pressure BioSciences for its development of a new, cutting-edge sample preparation technology for tissue and cell disruption and for the development of a method for the detergent-free extraction of proteins from lipid rich tissues. This novel approach combines the power of the Company?s Pressure Cycling Technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.
?Protein expression from lipid rich tissues is crucial to understanding many disease states such as obesity, heart disease, diabetes, and certain cancer types, among others,? says Frost & Sullivan Senior Research Analyst Sandhya Kamath. ?As a result, sample preparation is drawing attention in proteomic studies since it can affect the accuracy and the overall quality of the downstream analytical processes.?
For instance, conventional detergent-based methods used to extract proteins from tissues produce highly variable results. This increases the processing time for protein extraction as well as the costs, compromising the quantity and quality of the extracted proteins.
Pressure BioSciences offers an automated method of protein extraction that allows for optimal protein recovery.
?Unlike conventional methods of tissue delipidation that comprise several stages such as cell and tissue disruption, protein extraction from lipids, and partitioning, the new PCT-dependent sample preparation approach from Pressure BioSciences combines these complex stages into a single step, as a result of which the fractions of proteins and lipids generated from each sample can be analyzed individually, faster, more efficiently, and with more reproducibility,? notes Kamath. ?Moreover, this approach integrates PCT and reagents to extract and fractionate proteins from lipid-rich tissues in a detergent-free manner.?
Pressure BioSciences? PCT technology can be applied across genomic and proteomic sample preparation, enzyme control, pathogen inactivation, immunodiagnostics, and protein purification.
To enhance the proof of concept, scientists at Pressure BioSciences collaborated with researchers at the Harvard School of Public Health to carry out a research study on the comparative proteomic analysis of adipose tissue isolated from genetically different animal lines.
The study exposed differences in protein expression that could be the base for newer research in mechanistic studies of obesity and Type 2 diabetes. The firm?s researchers are also working to widen the scope of pressure-driven liquid-liquid extraction in biological samples.
In recognition of Pressure BioSciences? commendable innovation and the resulting technology advancement in the extraction and fractionation of proteins, Frost & Sullivan proudly presents it with the 2007 Award for Technology Innovation.
Each year, Frost & Sullivan presents this Award to the company that has demonstrated excellence in new products and technologies within their industry. The Award recognizes innovation through the launch of a broad line of emerging products and technologies.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Pressure BioSciences
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information, visit http://www.awards.frost.com.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday, November 26, 2007
SpaceDev Product Has First Flight into Space
SpaceDev Solar Array Actuators Launch Aboard WorldView-1 Satellite
Monday November 26, 1:28 pm ET
Launch Marks First Flight for Starsys Solar Array Rotational Drive and Control Electronics
POWAY, CA--(MARKET WIRE)--Nov 26, 2007 -- SpaceDev, Inc. (OTC BB: SPDV.OB) announced today the first flight of its new solar array rotational drive assemblies (SADA) and drive control electronics (DCE) aboard the Digitalglobe WorldView-1 satellite, launched September 18th from Vandenberg Air Force Base in California. SpaceDev produced the SADA and DCE under subcontract to Ball Aerospace. The system was commissioned shortly after the spacecraft reached orbit.
The Starsys Quiet Array Drive (QuAD) Micro-Stepping motion control technology was utilized on the Ball Aerospace BCP 2000 platform to articulate each of the two solar arrays and align them with the sun. The QuAD provides low disturbance actuation, allowing images to be captured at the same time that the arrays are being pointed, increasing the number of images captured by the spacecraft. Worldview 1 will provide images with 0.5-meter resolution.
"We wish to congratulate Digitalglobe and Ball Aerospace on the successful launch of Worldview 1. This launch is also an important milestone for us, being the first flight of our Starsys QuAD system. This enabling technology is also being used on two upcoming Ball Aerospace spacecraft: the NPOESS Precursor Mission and Worldview 2," said Mark Sirangelo, Chief Executive Officer and Chairman of the Board of SpaceDev. "We are proud to be playing a significant part in all of these programs and look forward to seeing the images provided by this groundbreaking spacecraft."
About SpaceDev
SpaceDev, Inc. is a space technology/aerospace company that creates and sells affordable and innovative space products and mission solutions. For more information, visit www.spacedev.com.
Except for factual statements made herein, this news release consists of forward-looking statements that involve risks that are difficult to predict. Words such as "believe," "intends," "expects," "anticipates" and variations thereof, identify forward-looking statements, although their absence does not mean a statement is not forward looking. Forward-looking statements are based on the Company's expectations, and are not guarantees of performance. The Company's actual results could differ materially from its current expectations. Factors that could contribute to such differences include risk associated with the Company's ability to manage schedule changes or cancellations, control costs and expenses, and obtain financing. Reference is also made to other factors described in the Company's periodic reports filed with the SEC. These forward-looking statements speak only as of the date of this release. SpaceDev does not intend to update these forward-looking statements.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=634086
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 26, 1:28 pm ET
Launch Marks First Flight for Starsys Solar Array Rotational Drive and Control Electronics
POWAY, CA--(MARKET WIRE)--Nov 26, 2007 -- SpaceDev, Inc. (OTC BB: SPDV.OB) announced today the first flight of its new solar array rotational drive assemblies (SADA) and drive control electronics (DCE) aboard the Digitalglobe WorldView-1 satellite, launched September 18th from Vandenberg Air Force Base in California. SpaceDev produced the SADA and DCE under subcontract to Ball Aerospace. The system was commissioned shortly after the spacecraft reached orbit.
The Starsys Quiet Array Drive (QuAD) Micro-Stepping motion control technology was utilized on the Ball Aerospace BCP 2000 platform to articulate each of the two solar arrays and align them with the sun. The QuAD provides low disturbance actuation, allowing images to be captured at the same time that the arrays are being pointed, increasing the number of images captured by the spacecraft. Worldview 1 will provide images with 0.5-meter resolution.
"We wish to congratulate Digitalglobe and Ball Aerospace on the successful launch of Worldview 1. This launch is also an important milestone for us, being the first flight of our Starsys QuAD system. This enabling technology is also being used on two upcoming Ball Aerospace spacecraft: the NPOESS Precursor Mission and Worldview 2," said Mark Sirangelo, Chief Executive Officer and Chairman of the Board of SpaceDev. "We are proud to be playing a significant part in all of these programs and look forward to seeing the images provided by this groundbreaking spacecraft."
About SpaceDev
SpaceDev, Inc. is a space technology/aerospace company that creates and sells affordable and innovative space products and mission solutions. For more information, visit www.spacedev.com.
Except for factual statements made herein, this news release consists of forward-looking statements that involve risks that are difficult to predict. Words such as "believe," "intends," "expects," "anticipates" and variations thereof, identify forward-looking statements, although their absence does not mean a statement is not forward looking. Forward-looking statements are based on the Company's expectations, and are not guarantees of performance. The Company's actual results could differ materially from its current expectations. Factors that could contribute to such differences include risk associated with the Company's ability to manage schedule changes or cancellations, control costs and expenses, and obtain financing. Reference is also made to other factors described in the Company's periodic reports filed with the SEC. These forward-looking statements speak only as of the date of this release. SpaceDev does not intend to update these forward-looking statements.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=634086
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Impressive Third Quarter Numbers Posted By China Kangtai
China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results
Monday November 26, 1:04 pm ET
Net Income up $1,036,024, or 89%, for the nine months ended September 30, 2007
HARBIN, China, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai Cactus Bio-tech Inc. (OTC BB: CKGT.OB), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based consumer products, filed its quarterly report on SEC Form 10QSB on November 19, 2007 and reported unaudited results for the period ended September 30, 2007. All results reported are in U.S. dollars.
For the three months ended September 30, 2007 net sales increased $1,145,545, or 41%, from $2,809,927 in 2006 to $3,955,472 in 2007. Net income for the September 30, 2007 quarter was $783,508, slightly lower than expected due to an increase in "provision for returns and doubtful accounts" of $188,348 and "income tax expense" of $109,073. Excluding these factors, net income would have increased more than 22%.
For the nine months ended September 30, 2007, net sales increased $2,694,828, or 37%, from $7,350,067 in 2006 to $10,044,895 in 2007. Net income for the same nine-month period increased $1,036,024, or 89% from $1,158,017, or $0.07 per share, in 2006 to $2,194,041, or $0.12 per share, in 2007.
Jinjiang Wang, Chief Executive Officer of China Kangtai Cactus Bio-tech Inc., commented, "The continued growth in our most recent quarterly results is attributable to a growing demand for our high quality cactus-based consumer products throughout China, as well as our continuing efforts to expand our production and distribution to better meet the market demand. The results demonstrate again that China Kangtai is a constantly profitable and growing company in a lucrative specialty food and beverage sector in China, which has huge growth potentials."
The company recognizes the fact that accounts receivable have increased to $4,673,504. However, the company believes this is a temporary phenomenon and is a result of company's fast expansions into new markets and aggressive marketing strategies.
During 2007, the company signed five new distributors, in addition to nine existing distributors. In order to encourage the existing distributors to order more products and the new distributors to enter new markets, the company provides them with incentives on top of the terms in the standard distribution agreements, including extended credit periods on outstanding balances. These strategies have proven to be effective in bringing about substantial sales growth by allowing quick entry into new markets and further penetration of existing markets.
These distributors are large trading companies with good credit ratings. Because the collection experiences with these distributors have been satisfactory, the company believes the possibility of delinquent accounts is very low and that the level of accounts receivable will decrease significantly towards the end of the year. Notwithstanding these facts, the company still increased the allowances significantly and, therefore, reduced book net income.
The company increased spending this quarter on advertising in new markets, new product R&D and IR campaigns. The company also incurred extra expenses on auditor fees for the three amended 10QSBs for 2006. While these expenses impacted the bottom line for the quarter, some of them are non-recurring and many represent higher than normal costs.
Despite the small drop in the net margin this quarter for the reasons discussed above, the company still has a healthy gross margin of almost 36% and a net margin of 20% for the quarter, and the company expects gross and net margins to continue to significantly improve.
China Kangtai is well on its way to comfortably beat its growth projections for the year of 2007. The company has conservatively projected to grow its revenues and earnings at a minimum rate of 30% annually without any external financing, but this year the company expects to realize a growth rate substantially higher than projected.
CEO Jinjiang Wang concluded, "Our company remains focused on creating more product categories and lines for distribution and is adopting a new distribution strategy to quickly and more efficiently penetrate new markets in China. With 15 product patents and 16 pending approval, China Kangtai is the dominant leader in the cactus-based consumer product sector in China."
About China Kangtai Cactus Bio-tech, Inc.
China Kangtai Cactus Bio-tech Inc. is market-leading cactus grower and producer of cactus-related products with over 387 acres of plants and an active R&D group that holds 15 product patents and is seeking another 16 in a variety of product categories. China Kangtai's high-quality products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 14 provinces and 4 municipalities.
Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking information about China Kangtai Cactus Bio-tech that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and China Kangtai Cactus Bio-tech future performance, operations and products.This forward-looking information should be considered only in connection with "Risk Factors" in China Kangtai Cactus Bio-tech's quarterly report on Form 10QSB filed with the SEC on November 19, 2007, and its other current and periodic reports filed with the SEC. China Kangtai Cactus Bio-tech assumes no obligations to update any forward-looking statements or information set forth in this press release.
For more information, please contact:
Ren Hu
Vice President
China Kangtai Cactus Bio-tech, Inc.
Tel: +1-201-887-0415
Email: Arenhu@gmail.com
Web: http://www.biocactus.com
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 26, 1:04 pm ET
Net Income up $1,036,024, or 89%, for the nine months ended September 30, 2007
HARBIN, China, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai Cactus Bio-tech Inc. (OTC BB: CKGT.OB), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based consumer products, filed its quarterly report on SEC Form 10QSB on November 19, 2007 and reported unaudited results for the period ended September 30, 2007. All results reported are in U.S. dollars.
For the three months ended September 30, 2007 net sales increased $1,145,545, or 41%, from $2,809,927 in 2006 to $3,955,472 in 2007. Net income for the September 30, 2007 quarter was $783,508, slightly lower than expected due to an increase in "provision for returns and doubtful accounts" of $188,348 and "income tax expense" of $109,073. Excluding these factors, net income would have increased more than 22%.
For the nine months ended September 30, 2007, net sales increased $2,694,828, or 37%, from $7,350,067 in 2006 to $10,044,895 in 2007. Net income for the same nine-month period increased $1,036,024, or 89% from $1,158,017, or $0.07 per share, in 2006 to $2,194,041, or $0.12 per share, in 2007.
Jinjiang Wang, Chief Executive Officer of China Kangtai Cactus Bio-tech Inc., commented, "The continued growth in our most recent quarterly results is attributable to a growing demand for our high quality cactus-based consumer products throughout China, as well as our continuing efforts to expand our production and distribution to better meet the market demand. The results demonstrate again that China Kangtai is a constantly profitable and growing company in a lucrative specialty food and beverage sector in China, which has huge growth potentials."
The company recognizes the fact that accounts receivable have increased to $4,673,504. However, the company believes this is a temporary phenomenon and is a result of company's fast expansions into new markets and aggressive marketing strategies.
During 2007, the company signed five new distributors, in addition to nine existing distributors. In order to encourage the existing distributors to order more products and the new distributors to enter new markets, the company provides them with incentives on top of the terms in the standard distribution agreements, including extended credit periods on outstanding balances. These strategies have proven to be effective in bringing about substantial sales growth by allowing quick entry into new markets and further penetration of existing markets.
These distributors are large trading companies with good credit ratings. Because the collection experiences with these distributors have been satisfactory, the company believes the possibility of delinquent accounts is very low and that the level of accounts receivable will decrease significantly towards the end of the year. Notwithstanding these facts, the company still increased the allowances significantly and, therefore, reduced book net income.
The company increased spending this quarter on advertising in new markets, new product R&D and IR campaigns. The company also incurred extra expenses on auditor fees for the three amended 10QSBs for 2006. While these expenses impacted the bottom line for the quarter, some of them are non-recurring and many represent higher than normal costs.
Despite the small drop in the net margin this quarter for the reasons discussed above, the company still has a healthy gross margin of almost 36% and a net margin of 20% for the quarter, and the company expects gross and net margins to continue to significantly improve.
China Kangtai is well on its way to comfortably beat its growth projections for the year of 2007. The company has conservatively projected to grow its revenues and earnings at a minimum rate of 30% annually without any external financing, but this year the company expects to realize a growth rate substantially higher than projected.
CEO Jinjiang Wang concluded, "Our company remains focused on creating more product categories and lines for distribution and is adopting a new distribution strategy to quickly and more efficiently penetrate new markets in China. With 15 product patents and 16 pending approval, China Kangtai is the dominant leader in the cactus-based consumer product sector in China."
About China Kangtai Cactus Bio-tech, Inc.
China Kangtai Cactus Bio-tech Inc. is market-leading cactus grower and producer of cactus-related products with over 387 acres of plants and an active R&D group that holds 15 product patents and is seeking another 16 in a variety of product categories. China Kangtai's high-quality products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 14 provinces and 4 municipalities.
Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking information about China Kangtai Cactus Bio-tech that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and China Kangtai Cactus Bio-tech future performance, operations and products.This forward-looking information should be considered only in connection with "Risk Factors" in China Kangtai Cactus Bio-tech's quarterly report on Form 10QSB filed with the SEC on November 19, 2007, and its other current and periodic reports filed with the SEC. China Kangtai Cactus Bio-tech assumes no obligations to update any forward-looking statements or information set forth in this press release.
For more information, please contact:
Ren Hu
Vice President
China Kangtai Cactus Bio-tech, Inc.
Tel: +1-201-887-0415
Email: Arenhu@gmail.com
Web: http://www.biocactus.com
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Alternative Energy Company H2 Diesel Is Making an Exiting Addition to its Management Team
H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer
Monday November 26, 8:30 am ET
HOUSTON, Nov. 26 /PRNewswire-FirstCall/ -- H2Diesel Holdings, Inc. (OTC BB: HTWO.OB) today announced the appointment of Cary J. Claiborne as Chief Financial Officer, effective December 1, 2007.
Since 2004, Mr. Claiborne has been the Chief Financial Officer of Osiris Therapeutics, Inc. where he led the Company's finance and information technology organizations and served as a strategic business partner to the Chairman of the Board and CEO. From 2001 to 2004, Mr. Claiborne was the Vice President of Financial Planning and Analysis at Constellation Energy, a Fortune 200 diversified energy company. At Constellation, he oversaw a budget consisting of $12 billion in revenue and over $500 million in net income. Prior to joining Constellation, Mr. Claiborne was the Vice President of Financial Planning and Analysis at Home Depot, Inc., where he oversaw a budget of $46 billion in revenue and $3 billion in net income. Before joining Home Depot, Mr. Claiborne was also the Vice President of Financial Planning and Analysis at MCI Corporation, where he supervised the financial planning and analysis activities for MCI's Core Communications group.
Mr. Claiborne, 47, began his career at General Electric in 1982, where he held numerous senior management positions, leading to President and CEO of New Enterprise Wholesale Services in 1996. In this role, he directed the business activities of an $80 million telecommunications reseller. Prior to this position, he was Senior Vice President and CFO of GE Capital Business Services and Director of Operations Analysis for GE Capital.
Mr. Claiborne earned an MBA in Finance from Villanova University and a BA in business administration from Rutgers University.
"I am thrilled to be welcoming Cary Claiborne to the H2Diesel team," stated David Gillespie, President and Chief Executive Officer of H2Diesel. "Cary's depth of experience in both large and small company settings provides him with a unique perspective that will prove invaluable to H2Diesel as we seek to commercialize our proprietary renewable biofuel."
"I am extremely excited to be joining the H2Diesel management team," noted Mr. Claiborne. "I believe that the company is at a major inflection point in its history, in an industry that has significant growth potential. I look forward to leveraging my experience and capabilities to help make H2Diesel a leader in this rapidly emerging renewable energy field."
About H2Diesel Holdings, Inc.
H2Diesel is a development stage company that holds an exclusive license for North America, Central America and the Caribbean to exploit proprietary technology to manufacture an alternative biofuel from vegetable oils and animal fats that is intended to be marketed as a new class of renewable fuel or fuel additive for power generation, heavy equipment, marine use or as heating fuel. We believe our biofuel could provide a cheaper, renewable alternative energy source with significantly lower emissions than traditional fuels and a cleaner and more efficient alternative to heating oil. Our business model calls for establishing biofuel production facilities directly and through sublicensing of our technology to qualified licensees.
This news release contains forward-looking statements. These forward- looking statements concern the Company's operations, prospects, plans, economic performance and financial condition and are based largely on the Company's beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 and Current Report on Form 8-K filed on October 18, 2007.
CONTACT:
David Gillespie,
President & CEO
H2Diesel Holdings, Inc.
713-973-5720
Rob Schatz
Alisa D. Steinberg (Media)
Wolfe Axelrod Weinberger Associates, LLC
212-370-4500
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 26, 8:30 am ET
HOUSTON, Nov. 26 /PRNewswire-FirstCall/ -- H2Diesel Holdings, Inc. (OTC BB: HTWO.OB) today announced the appointment of Cary J. Claiborne as Chief Financial Officer, effective December 1, 2007.
Since 2004, Mr. Claiborne has been the Chief Financial Officer of Osiris Therapeutics, Inc. where he led the Company's finance and information technology organizations and served as a strategic business partner to the Chairman of the Board and CEO. From 2001 to 2004, Mr. Claiborne was the Vice President of Financial Planning and Analysis at Constellation Energy, a Fortune 200 diversified energy company. At Constellation, he oversaw a budget consisting of $12 billion in revenue and over $500 million in net income. Prior to joining Constellation, Mr. Claiborne was the Vice President of Financial Planning and Analysis at Home Depot, Inc., where he oversaw a budget of $46 billion in revenue and $3 billion in net income. Before joining Home Depot, Mr. Claiborne was also the Vice President of Financial Planning and Analysis at MCI Corporation, where he supervised the financial planning and analysis activities for MCI's Core Communications group.
Mr. Claiborne, 47, began his career at General Electric in 1982, where he held numerous senior management positions, leading to President and CEO of New Enterprise Wholesale Services in 1996. In this role, he directed the business activities of an $80 million telecommunications reseller. Prior to this position, he was Senior Vice President and CFO of GE Capital Business Services and Director of Operations Analysis for GE Capital.
Mr. Claiborne earned an MBA in Finance from Villanova University and a BA in business administration from Rutgers University.
"I am thrilled to be welcoming Cary Claiborne to the H2Diesel team," stated David Gillespie, President and Chief Executive Officer of H2Diesel. "Cary's depth of experience in both large and small company settings provides him with a unique perspective that will prove invaluable to H2Diesel as we seek to commercialize our proprietary renewable biofuel."
"I am extremely excited to be joining the H2Diesel management team," noted Mr. Claiborne. "I believe that the company is at a major inflection point in its history, in an industry that has significant growth potential. I look forward to leveraging my experience and capabilities to help make H2Diesel a leader in this rapidly emerging renewable energy field."
About H2Diesel Holdings, Inc.
H2Diesel is a development stage company that holds an exclusive license for North America, Central America and the Caribbean to exploit proprietary technology to manufacture an alternative biofuel from vegetable oils and animal fats that is intended to be marketed as a new class of renewable fuel or fuel additive for power generation, heavy equipment, marine use or as heating fuel. We believe our biofuel could provide a cheaper, renewable alternative energy source with significantly lower emissions than traditional fuels and a cleaner and more efficient alternative to heating oil. Our business model calls for establishing biofuel production facilities directly and through sublicensing of our technology to qualified licensees.
This news release contains forward-looking statements. These forward- looking statements concern the Company's operations, prospects, plans, economic performance and financial condition and are based largely on the Company's beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 and Current Report on Form 8-K filed on October 18, 2007.
CONTACT:
David Gillespie,
President & CEO
H2Diesel Holdings, Inc.
713-973-5720
Rob Schatz
Alisa D. Steinberg (Media)
Wolfe Axelrod Weinberger Associates, LLC
212-370-4500
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
An Exciting Specialty Pharmaceutical Company Presenting at Lazard Capital Markets Conference
Osteologix to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Monday November 26, 8:15 am ET
Live Webcast Scheduled November 28, 10:00 a.m. EST
SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB) today announced that Philip J. Young, president and CEO of Osteologix, will present a corporate overview Wednesday, November 28, at 10:00 a.m. EST during the Lazard Capital Markets 4th Annual Healthcare Conference at the New York Palace Hotel in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.osteologix.com and clicking the link provided under 'Latest News'. An archived presentation will be available for 90 days.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company's vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 26, 8:15 am ET
Live Webcast Scheduled November 28, 10:00 a.m. EST
SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB) today announced that Philip J. Young, president and CEO of Osteologix, will present a corporate overview Wednesday, November 28, at 10:00 a.m. EST during the Lazard Capital Markets 4th Annual Healthcare Conference at the New York Palace Hotel in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.osteologix.com and clicking the link provided under 'Latest News'. An archived presentation will be available for 90 days.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company's vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
New Research Out On A Company With A New Answer to Global Warming.
Carbon Sciences Inc. Rated 'Speculative Buy,' by Beacon Equity Research
Monday November 26, 6:00 am ET
DALLAS--(BUSINESS WIRE)--Carbon Sciences (Other OTC: CABN.OB) has been rated "speculative Buy" by Beacon Equity Research Analyst, Victor Sula, PhD.
The full report is available at http://www.BeaconEquityResearch.com.
Anyone interested in receiving alerts regarding Carbon Sciences Inc. research should email members@beaconequityresearch.com with "CABN" in the subject line.
In the report, the analyst writes, "Carbon Sciences, Inc. (CABN) is developing an innovative technology for transforming harmful carbon dioxide (CO2) into earth-friendly carbon products such as building materials, fertilizers and plastics. The technology is based on a patent filed by the Company and developed under the brand name, GreenCarbon? Technology. By eliminating harmful CO2 emissions, the technology will provide a partial solution to the problem of global warming."
GreenCarbon? Technology is initially targeting emissions from coal-fired electrical power and fuel production plants, since about one-third of CO2 released into the atmosphere is from the combustion of coal. Coal is increasingly in use as a power plant fuel substitute for oil and gas. The International Energy Agency estimates overall world coal use will increase 50% by 2030.?
Other companies in the clean energy sector include Fuel-Tech Inc. (NASDAQ: FTEK - News), CECO Environmental Corp (NASDAQ: CECE - News), China Tech Development (NASDAQ: CTDC - News), and NuCo2 Inc. (NASDAQ: NUCO - News)
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Carbon Sciences (CABN). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Principals of BER have purchased 300,000 shares of restricted stock from the company (CABN) at .15 per share. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 26, 6:00 am ET
DALLAS--(BUSINESS WIRE)--Carbon Sciences (Other OTC: CABN.OB) has been rated "speculative Buy" by Beacon Equity Research Analyst, Victor Sula, PhD.
The full report is available at http://www.BeaconEquityResearch.com.
Anyone interested in receiving alerts regarding Carbon Sciences Inc. research should email members@beaconequityresearch.com with "CABN" in the subject line.
In the report, the analyst writes, "Carbon Sciences, Inc. (CABN) is developing an innovative technology for transforming harmful carbon dioxide (CO2) into earth-friendly carbon products such as building materials, fertilizers and plastics. The technology is based on a patent filed by the Company and developed under the brand name, GreenCarbon? Technology. By eliminating harmful CO2 emissions, the technology will provide a partial solution to the problem of global warming."
GreenCarbon? Technology is initially targeting emissions from coal-fired electrical power and fuel production plants, since about one-third of CO2 released into the atmosphere is from the combustion of coal. Coal is increasingly in use as a power plant fuel substitute for oil and gas. The International Energy Agency estimates overall world coal use will increase 50% by 2030.?
Other companies in the clean energy sector include Fuel-Tech Inc. (NASDAQ: FTEK - News), CECO Environmental Corp (NASDAQ: CECE - News), China Tech Development (NASDAQ: CTDC - News), and NuCo2 Inc. (NASDAQ: NUCO - News)
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Carbon Sciences (CABN). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Principals of BER have purchased 300,000 shares of restricted stock from the company (CABN) at .15 per share. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday, November 21, 2007
Onstream Media Partners Up With one of New York's Largest Video Production Companies
Tuesday November 20, 2:47 pm ET
POMPANO BEACH, Fla., Nov. 20 /PRNewswire-FirstCall/ -- Onstream Media Corporation (NasdaqCM: ONSM), a leading webcast services provider, announced today that New York based All Mobile Video (AMV), one of New York's largest video production companies has agreed to integrate Onstream Media's Visual Webcaster on-site webcasting systems into their production studios to offer their clients a seamless webcasting solution. All Mobile Video and Onstream Media, after several years of cooperative production of webcasts, have created this partnership to promote and produce webcasting as well as digital asset management solutions. As a leading video broadcasting company in New York, AMV operates seven production studios in Manhattan, 21 video satellite and production trucks and has 200 employees.
AMV's President, Eric Duke, stated, "Our expanded partnership with Onstream Media will enable us to provide state-of-the-art webcast services in addition to our already world class broadcast production capabilities. Our success has been based on providing the best personnel using the best equipment to produce the most demanding events and as a result of this partnership we can now expand that philosophy to webcasting events."
Randy Selman, President and Chief Executive Officer of Onstream Media, stated, "AMV is the one of the most respected providers of video production services and has been referring clients to Onstream Media for several years. As a result of this agreement we are extending the relationship to include joint marketing of all our web based digital media services including our latest on-site encoding technology for webcasting and our Digital Media Services Platform (DMSP). This partnership further enhances Onstream Media's capabilities to service the professional broadcast industry right at the production source resulting in the best quality productions and user experiences."
About All Mobile Video
All Mobile Video is the country's premier provider of end-to-end video and audio solutions for entertainment, sports, and news programming and events. AMV offers the full spectrum of services including spacious Manhattan based sound stages with full post-production capabilities as well as mobile production and editing trucks and extensive uplink solutions.
All Mobile Video has handled every size and type of event - from professional and NCAA sporting events and internationally viewed awards shows to live documentaries, corporate communication events and daily television broadcasts.
About Onstream Media:
Onstream Media Corporation (NasdaqCM: ONSM) is an online service provider of live and on-demand internet video, corporate web communications and content management applications. Onstream Media's pioneering Digital Media Services Platform (DMSP) provides customers with cost effective tools for encoding, managing, indexing, and publishing content via the Internet. The DMSP provides our clients with intelligent delivery and syndication of video advertising, and supports pay-per-view for online video and other rich media assets. The DMSP also provides an efficient workflow for transcoding and publishing user- generated content in combination with social networks and online video classifieds. In addition, Onstream Media provides live and on-demand webcasting, webinars, web and audio conferencing services. In fact, almost half of the Fortune 1000 companies and 78% of the Fortune 100 CEOs and CFOs have used Onstream Media's services.
Select Onstream Media customers include: AOL, AAA, AXA Equitable Life Insurance Company, Bonnier Corporation, Dell, Deutsche Bank, Disney, National Press Club, NHL, MGM, PR Newswire, Rodale, Inc., Televisa, WireOne, Shareholder.com (NASDAQ), and the U.S. Government. Onstream Media's strategic relationships include Akamai, Adobe, eBay, FiveAcross/Cisco and Qwest. For more information, visit Onstream Media at http://www.onstreammedia.com/ or call 954-917-6655.
Certain statements in this document and elsewhere by Onstream Media are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. economy; government policies and regulations, including, but not limited to those affecting the Internet. Onstream Media undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in Onstream Media Corporation's filings with the Securities and Exchange Commission.
Media Relations: Beth Amorosi
FastLane Communications
973.582.3498
bamorosi@fast-lane.net
Investor Relations:
Brett Maas
Hayden Communications
646-536-7331
brett@haydenir.com
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
POMPANO BEACH, Fla., Nov. 20 /PRNewswire-FirstCall/ -- Onstream Media Corporation (NasdaqCM: ONSM), a leading webcast services provider, announced today that New York based All Mobile Video (AMV), one of New York's largest video production companies has agreed to integrate Onstream Media's Visual Webcaster on-site webcasting systems into their production studios to offer their clients a seamless webcasting solution. All Mobile Video and Onstream Media, after several years of cooperative production of webcasts, have created this partnership to promote and produce webcasting as well as digital asset management solutions. As a leading video broadcasting company in New York, AMV operates seven production studios in Manhattan, 21 video satellite and production trucks and has 200 employees.
AMV's President, Eric Duke, stated, "Our expanded partnership with Onstream Media will enable us to provide state-of-the-art webcast services in addition to our already world class broadcast production capabilities. Our success has been based on providing the best personnel using the best equipment to produce the most demanding events and as a result of this partnership we can now expand that philosophy to webcasting events."
Randy Selman, President and Chief Executive Officer of Onstream Media, stated, "AMV is the one of the most respected providers of video production services and has been referring clients to Onstream Media for several years. As a result of this agreement we are extending the relationship to include joint marketing of all our web based digital media services including our latest on-site encoding technology for webcasting and our Digital Media Services Platform (DMSP). This partnership further enhances Onstream Media's capabilities to service the professional broadcast industry right at the production source resulting in the best quality productions and user experiences."
About All Mobile Video
All Mobile Video is the country's premier provider of end-to-end video and audio solutions for entertainment, sports, and news programming and events. AMV offers the full spectrum of services including spacious Manhattan based sound stages with full post-production capabilities as well as mobile production and editing trucks and extensive uplink solutions.
All Mobile Video has handled every size and type of event - from professional and NCAA sporting events and internationally viewed awards shows to live documentaries, corporate communication events and daily television broadcasts.
About Onstream Media:
Onstream Media Corporation (NasdaqCM: ONSM) is an online service provider of live and on-demand internet video, corporate web communications and content management applications. Onstream Media's pioneering Digital Media Services Platform (DMSP) provides customers with cost effective tools for encoding, managing, indexing, and publishing content via the Internet. The DMSP provides our clients with intelligent delivery and syndication of video advertising, and supports pay-per-view for online video and other rich media assets. The DMSP also provides an efficient workflow for transcoding and publishing user- generated content in combination with social networks and online video classifieds. In addition, Onstream Media provides live and on-demand webcasting, webinars, web and audio conferencing services. In fact, almost half of the Fortune 1000 companies and 78% of the Fortune 100 CEOs and CFOs have used Onstream Media's services.
Select Onstream Media customers include: AOL, AAA, AXA Equitable Life Insurance Company, Bonnier Corporation, Dell, Deutsche Bank, Disney, National Press Club, NHL, MGM, PR Newswire, Rodale, Inc., Televisa, WireOne, Shareholder.com (NASDAQ), and the U.S. Government. Onstream Media's strategic relationships include Akamai, Adobe, eBay, FiveAcross/Cisco and Qwest. For more information, visit Onstream Media at http://www.onstreammedia.com/ or call 954-917-6655.
Certain statements in this document and elsewhere by Onstream Media are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. economy; government policies and regulations, including, but not limited to those affecting the Internet. Onstream Media undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in Onstream Media Corporation's filings with the Securities and Exchange Commission.
Media Relations: Beth Amorosi
FastLane Communications
973.582.3498
bamorosi@fast-lane.net
Investor Relations:
Brett Maas
Hayden Communications
646-536-7331
brett@haydenir.com
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday, November 20, 2007
Perfisans Recieves a Big Order From China Cell Phone Company
Tiffany Technology Ltd., Set to Merge with Perfisans, Will Start Cellular Phone Production
Toronto, Ontario, CANADA, Nov. 20, 2007 (PRIME NEWSWIRE) -- Perfisans Holdings Inc. (OTC BB: PFHD), a next-generation, semiconductor design house focused on the high-speed wireless communication and consumer semiconductor markets, today announced the receipt of a cellular phone order from China valued at US$100,000.
Perfisans is in the process of merging with Tiffany Technology Ltd., a major channel distributor focused on consumer semiconductor components and supply to the ever-increasing electronics markets in China and worldwide. Perfisans recently announced change of the company name to Aspire International Inc. to reflect the new globalization business plan of the company.
Perfisans has formed an implementation team in China to develop cellular phone solutions based on the Company’s in-depth engineering knowledge and expertise. The cellular phone solution released recently to the market has enabled Tiffany Technology Ltd. to secure a US$4 million contract. Assembly line production for the cell phone designs will start after customer-focused quality assurance testing for software and hardware engineering is complete.
The rapid growth of the cellular phone market is especially evident in China where new cellular subscriptions have surpassed fixed telephone lines. The ability to adapt to the rapidly changing market and to roll out new products quickly will be a high priority for Perfisans in this endeavor.
About Persifans Holdings, Inc.
Founded in 2001, Perfisans Holdings, Inc. is headquartered in the high-tech zone of Markham, Ontario, Canada, where companies such as AMD, IBM, and Motorola are located.
Perfisans is a fabless semiconductor company focused on developing leading edge, cost-effective, system-on-chip (SOC) integrated circuits (IC) and delivering innovative solutions that address the performance needs of next generation semiconductor market demand. The Company's technologies have applications in data-telecommunication, storage networks, content delivery networks, broadband networks, rich streaming media, broadband wireless and wireless surveillance and cellular phone applications.
More information can be obtained from the Company's web site at http://www.perfisans.com/.
About Tiffany Technology, Ltd.
Tiffany Technology Ltd., a Hong Kong corporation founded in August 2005, is an electronics product channel distribution company that focuses on sales and marketing of the fashionable consumer electronics products and delivers high-quality services to customers in mainland China and the Asia Pacific region.
The Company’s mission is to provide superior services, fast turnaround time, fast shipment, and a rich portfolio of products for manufacturers.
More information can be obtained from the Company's web site at http://www.tiffanytech.com/
Cautionary Statement
This press release contains statements relating to future results of Perfisans (including certain projections and business trends) that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: the cyclical nature of the semiconductor industry and the markets addressed by the company's and its customers' products; demand for and market acceptance of new and existing products; successful development of new products; the timing of new product introductions; changes in product mix; product obsolescence; the availability of manufacturing capacity; fluctuations in manufacturing yields; pricing pressures and other competitive factors; the ability to develop and implement new technologies and to obtain protection for the related intellectual property; the uncertainties of litigation; our ability to attract and retain qualified personnel; as well as other risks and uncertainties, including those detailed from time to time in Perfisans' Securities and Exchange Commission filings. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Contact:
Perfisans Holdings, Inc./Aspire International, I
nc.Investor Relations
(905)943-9996 x 230
ir@perfisans.com
OR
RedChip Companies, Inc.
Dave Gentry
(800) REDCHIP (733-2447), ext. 104
dave@redchip.com
Toronto, Ontario, CANADA, Nov. 20, 2007 (PRIME NEWSWIRE) -- Perfisans Holdings Inc. (OTC BB: PFHD), a next-generation, semiconductor design house focused on the high-speed wireless communication and consumer semiconductor markets, today announced the receipt of a cellular phone order from China valued at US$100,000.
Perfisans is in the process of merging with Tiffany Technology Ltd., a major channel distributor focused on consumer semiconductor components and supply to the ever-increasing electronics markets in China and worldwide. Perfisans recently announced change of the company name to Aspire International Inc. to reflect the new globalization business plan of the company.
Perfisans has formed an implementation team in China to develop cellular phone solutions based on the Company’s in-depth engineering knowledge and expertise. The cellular phone solution released recently to the market has enabled Tiffany Technology Ltd. to secure a US$4 million contract. Assembly line production for the cell phone designs will start after customer-focused quality assurance testing for software and hardware engineering is complete.
The rapid growth of the cellular phone market is especially evident in China where new cellular subscriptions have surpassed fixed telephone lines. The ability to adapt to the rapidly changing market and to roll out new products quickly will be a high priority for Perfisans in this endeavor.
About Persifans Holdings, Inc.
Founded in 2001, Perfisans Holdings, Inc. is headquartered in the high-tech zone of Markham, Ontario, Canada, where companies such as AMD, IBM, and Motorola are located.
Perfisans is a fabless semiconductor company focused on developing leading edge, cost-effective, system-on-chip (SOC) integrated circuits (IC) and delivering innovative solutions that address the performance needs of next generation semiconductor market demand. The Company's technologies have applications in data-telecommunication, storage networks, content delivery networks, broadband networks, rich streaming media, broadband wireless and wireless surveillance and cellular phone applications.
More information can be obtained from the Company's web site at http://www.perfisans.com/.
About Tiffany Technology, Ltd.
Tiffany Technology Ltd., a Hong Kong corporation founded in August 2005, is an electronics product channel distribution company that focuses on sales and marketing of the fashionable consumer electronics products and delivers high-quality services to customers in mainland China and the Asia Pacific region.
The Company’s mission is to provide superior services, fast turnaround time, fast shipment, and a rich portfolio of products for manufacturers.
More information can be obtained from the Company's web site at http://www.tiffanytech.com/
Cautionary Statement
This press release contains statements relating to future results of Perfisans (including certain projections and business trends) that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: the cyclical nature of the semiconductor industry and the markets addressed by the company's and its customers' products; demand for and market acceptance of new and existing products; successful development of new products; the timing of new product introductions; changes in product mix; product obsolescence; the availability of manufacturing capacity; fluctuations in manufacturing yields; pricing pressures and other competitive factors; the ability to develop and implement new technologies and to obtain protection for the related intellectual property; the uncertainties of litigation; our ability to attract and retain qualified personnel; as well as other risks and uncertainties, including those detailed from time to time in Perfisans' Securities and Exchange Commission filings. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Contact:
Perfisans Holdings, Inc./Aspire International, I
nc.Investor Relations
(905)943-9996 x 230
ir@perfisans.com
OR
RedChip Companies, Inc.
Dave Gentry
(800) REDCHIP (733-2447), ext. 104
dave@redchip.com
Monday, November 19, 2007
ZYTO and RedChip Joining Forces To Let the Word Out About This Great Company
ZYTO Corporation Announces Engagement of RedChip Companies to Lead Investor Relations
Monday November 19, 1:49 pm ET
OREM, Utah--(BUSINESS WIRE)--ZYTO? Corp. (PNK: ZYTC.PK), a biotechnology company that uses quantum science to enable computers to communicate with the human body and mind, today announced that it has hired RedChip Companies Inc. to lead its investor relations program.
"We chose RedChip Companies to lead our investor relations program because of the company?s proven record for helping emerging growth companies increase investor awareness, as well as their integrity and solid reputation for providing measurable results," said Dr. Vaughn R. Cook, president and CEO of ZYTO Corp. "We look forward to working with RedChip as part of our team, and are confident its programs will bring value to our company and investors," he added.
ZYTO Corp. is a biotechnology company that uses quantum science to enable computers to communicate with the human body and mind. As the global leader in bio-communication technology, ZYTO stands at the cutting edge of two decades of technological evolution. The staff at ZYTO specialize in the design of systems that interface computers with living things to facilitate the transfer of information between them.
ZYTO technology revolutionizes the way people make decisions. ZYTO Corp. provides additional information at http://www.zyto.com/.
"We are very pleased with the opportunity to represent ZYTO Corporation. The Company?s computerized biotechnologies are innovative and offer real-world applications for the health care industry. We look forward to leveraging a comprehensive investor relations program for ZYTO and introducing them to RedChip's international retail and institutional network," commented Dave Gentry, president of RedChip Companies Inc.
About ZYTO Corp.
ZYTO Corp. is a biotechnology company that uses quantum science to enable computers to communicate with the human body and mind. ZYTO technology revolutionizes the way people make decisions.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 19, 1:49 pm ET
OREM, Utah--(BUSINESS WIRE)--ZYTO? Corp. (PNK: ZYTC.PK), a biotechnology company that uses quantum science to enable computers to communicate with the human body and mind, today announced that it has hired RedChip Companies Inc. to lead its investor relations program.
"We chose RedChip Companies to lead our investor relations program because of the company?s proven record for helping emerging growth companies increase investor awareness, as well as their integrity and solid reputation for providing measurable results," said Dr. Vaughn R. Cook, president and CEO of ZYTO Corp. "We look forward to working with RedChip as part of our team, and are confident its programs will bring value to our company and investors," he added.
ZYTO Corp. is a biotechnology company that uses quantum science to enable computers to communicate with the human body and mind. As the global leader in bio-communication technology, ZYTO stands at the cutting edge of two decades of technological evolution. The staff at ZYTO specialize in the design of systems that interface computers with living things to facilitate the transfer of information between them.
ZYTO technology revolutionizes the way people make decisions. ZYTO Corp. provides additional information at http://www.zyto.com/.
"We are very pleased with the opportunity to represent ZYTO Corporation. The Company?s computerized biotechnologies are innovative and offer real-world applications for the health care industry. We look forward to leveraging a comprehensive investor relations program for ZYTO and introducing them to RedChip's international retail and institutional network," commented Dave Gentry, president of RedChip Companies Inc.
About ZYTO Corp.
ZYTO Corp. is a biotechnology company that uses quantum science to enable computers to communicate with the human body and mind. ZYTO technology revolutionizes the way people make decisions.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
The Makers of Celsius the First Calorie Burning Soda Talk with WallSt. net
CEO Steve Haley Interviewed by WallSt.net
Monday November 19, 9:48 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Nov 19, 2007 -- Steve Haley, Chief Executive Officer of Celsius Holdings, Inc (OTC BB: CSUH.OB) is featured in an exclusive interview with http://www.wallst.net/ on November 16. The interview is posted on http://www.wallst.net/ and http://www.celsius.com/.
The interview will cover topics including Celsius Holdings' market potential, growth initiatives, competitive edge, recent news, and milestones for investors to watch for.
To hear the interview in its entirety, visit the company's website http://www.celsius.com/ and click on investor information or visit http://www.wallst.net/, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window once it is posted.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly owned operating subsidiary, Celsius, Inc. Celsius Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the negative calorie beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets in all geographies. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. Celsius is available through multiple channels including grocery, drug, convenience stores, gyms and nutrition stores. Celsius is proudly carried by fine establishments such as Raleys, Vitamin Shoppe, Hi-Health, Valero Corner Stores, Diamond Shamrock, Hannaford Supermarkets, Heinens, Sweetbay Supermarkets, Discount Drug Mart, King Soopers, Krogers, Dillions, Fry's, Smiths, Gelsons, Market Baskets, Bristol Farms and Central Markets. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com/. For investor information, please visit http://www.redchip.com/.
About WallSt.net:
http://www.wallst.net/ is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net/, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com/), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com/), a business and finance podcast Web site. WallSt.net will not receive any compensation for the dissemination of the interview.
About Celsius®
Celsius is the first healthy calorie burning beverage that delivers great taste and sustained energy, back by trusted science. Celsius in multiple clinical studies has been shown to burn calories, boost energy and increase metabolism for up to 3 hours. In the most recent study conducted at the University of Oklahoma and released at the International Society of Sports Nutrition, Celsius was shown to burn more than 100 calories. Celsius contains a blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C. Celsius contains none of the bad ingredients typically found in many drinks -- no sugar, no carbs, no preservatives, no high fructose corn syrup, no trans fats, and it has very little sodium. Celsius is available in 5 great-tasting flavors including Orange, Cola, Lemon-Lime, Wild Berry and Ginger Ale.
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed in our reports Celsius Holdings files from time to time with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 19, 9:48 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Nov 19, 2007 -- Steve Haley, Chief Executive Officer of Celsius Holdings, Inc (OTC BB: CSUH.OB) is featured in an exclusive interview with http://www.wallst.net/ on November 16. The interview is posted on http://www.wallst.net/ and http://www.celsius.com/.
The interview will cover topics including Celsius Holdings' market potential, growth initiatives, competitive edge, recent news, and milestones for investors to watch for.
To hear the interview in its entirety, visit the company's website http://www.celsius.com/ and click on investor information or visit http://www.wallst.net/, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window once it is posted.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly owned operating subsidiary, Celsius, Inc. Celsius Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the negative calorie beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets in all geographies. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. Celsius is available through multiple channels including grocery, drug, convenience stores, gyms and nutrition stores. Celsius is proudly carried by fine establishments such as Raleys, Vitamin Shoppe, Hi-Health, Valero Corner Stores, Diamond Shamrock, Hannaford Supermarkets, Heinens, Sweetbay Supermarkets, Discount Drug Mart, King Soopers, Krogers, Dillions, Fry's, Smiths, Gelsons, Market Baskets, Bristol Farms and Central Markets. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com/. For investor information, please visit http://www.redchip.com/.
About WallSt.net:
http://www.wallst.net/ is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net/, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com/), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com/), a business and finance podcast Web site. WallSt.net will not receive any compensation for the dissemination of the interview.
About Celsius®
Celsius is the first healthy calorie burning beverage that delivers great taste and sustained energy, back by trusted science. Celsius in multiple clinical studies has been shown to burn calories, boost energy and increase metabolism for up to 3 hours. In the most recent study conducted at the University of Oklahoma and released at the International Society of Sports Nutrition, Celsius was shown to burn more than 100 calories. Celsius contains a blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C. Celsius contains none of the bad ingredients typically found in many drinks -- no sugar, no carbs, no preservatives, no high fructose corn syrup, no trans fats, and it has very little sodium. Celsius is available in 5 great-tasting flavors including Orange, Cola, Lemon-Lime, Wild Berry and Ginger Ale.
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed in our reports Celsius Holdings files from time to time with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Revolutionary Efforts in Alternative Energy as Oil Price Rises
Record High Oil Prices Illuminate Unique Competitive Advantage for BioSolar's Bioplastic Solar Cell Components, Says CEO in Interview
Monday November 19, 9:05 am ET
SANTA CLARITA, CA--(MARKET WIRE)--Nov 19, 2007 -- BioSolar(TM), Inc. (OTC BB: BSRC.OB), developer of a breakthrough technology to produce bioplastic materials from renewable plant sources that reduce the cost of photovoltaic solar cells, today reports that the company's CEO has been interviewed for the CEOcast network. In the interview, BioSolar's CEO, Dr. David Lee, discusses how BioSolar's durable bio-based plastics products are expected to benefit from an increasing competitive advantage in the wake of soaring crude oil prices.
"We can make solar cells truly a green energy source by replacing the petroleum-based components with plastics made from sustainable sources. The higher oil prices go, the more powerful our cost advantage. While we're in this business because we are driven to do the right thing for the planet, we are also driven to build a profitable business," commented Dr. Lee. "This $16 billion industry is growing at nearly 40% per year, and given that our cost advantages become ever more powerful as petroleum prices move higher, we expect to capture market penetration at rates much higher than the industry growth rates."
The interview is available on the company's website at: www.biosolar.com/investors.php. Click on the "Play Arrow" on the media player.
About BioSolar, Inc.
BioSolar, Inc. is developing a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost per watt of solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost. BioSolar is the first company to introduce a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. To learn more about BioSolar, please visit our website at http://www.biosolar.com/.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 19, 9:05 am ET
SANTA CLARITA, CA--(MARKET WIRE)--Nov 19, 2007 -- BioSolar(TM), Inc. (OTC BB: BSRC.OB), developer of a breakthrough technology to produce bioplastic materials from renewable plant sources that reduce the cost of photovoltaic solar cells, today reports that the company's CEO has been interviewed for the CEOcast network. In the interview, BioSolar's CEO, Dr. David Lee, discusses how BioSolar's durable bio-based plastics products are expected to benefit from an increasing competitive advantage in the wake of soaring crude oil prices.
"We can make solar cells truly a green energy source by replacing the petroleum-based components with plastics made from sustainable sources. The higher oil prices go, the more powerful our cost advantage. While we're in this business because we are driven to do the right thing for the planet, we are also driven to build a profitable business," commented Dr. Lee. "This $16 billion industry is growing at nearly 40% per year, and given that our cost advantages become ever more powerful as petroleum prices move higher, we expect to capture market penetration at rates much higher than the industry growth rates."
The interview is available on the company's website at: www.biosolar.com/investors.php. Click on the "Play Arrow" on the media player.
About BioSolar, Inc.
BioSolar, Inc. is developing a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost per watt of solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost. BioSolar is the first company to introduce a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. To learn more about BioSolar, please visit our website at http://www.biosolar.com/.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Southern Star Completes Frac on the R.C. Atkins 8-1
Monday November 19, 9:00 am ET
HOUSTON--(BUSINESS WIRE)--Southern Star Energy Inc., (OTC BB: SSEY.OB) is pleased to provide an update the company?s well the R.C. Atkins 8-1.R.C. Atkins 8-1: Drilled and completed February 24, 2007 to depth of 9950 feet. First stage completion with perforations from 9084? thru 9291? was perforated and frac stimulated with a conventional ball out procedure from September 25 through September 27. The well was allowed to flow back and clean up to tanks until October 19 when operations commenced to complete the Upper Cotton Valley section from 8500? to 8876?. The Upper Cotton Valley section from 8500? through 8876? was completed utilizing the new coiled tubing conveyed minifrac method in six stages from October 19 through October 25. The well was allowed to flow back completion fluids up 4.5 inch casing and clean up over the next eight days (November 1) at which time it began to show traces of hydrocarbons. From November 1 through November 10, gas rates flowing up casing have built up to about 740 mcfpd and 25 bwph with flowing casing pressure of 575 psi. Production has stabilized at 505 mcfpd 30 bwph at flowing casing pressure of 575 psi on 24/64 choke. From November 12 through 14, a completion rig was set up running production tubing into the well. Also a 150 foot sales line has been installed to begin producing the well to sales.
All of the estimated recoverable oil and gas reserves in different zones are confirmed by mudlog, wireline logs evaluations and in some cases with sidewall cores and Formation Tester pressure measurement. Total of 64 feet estimated gas pay is distributed over a gross (total) interval of 900 feet in the Cotton Valley section. Three shallower zones demonstrating primarily oil potential will continue to be evaluated in subsequent wells. Results of those evaluations will determine the feasibility of additional future developments targeting the oil potential. The zones indicating oil potential are regionally known and have been economically developed within a ten mile radius of this well.
Further Information
Shareholders and prospective investors are encouraged to visit Southern Star Energy?s website: www.ssenergyinc.com to learn more about the Company and the Cotton Valley Trend. Please feel free to call investor relations at 1-800-733-2447 ext. 107 to receive a full corporate investor package.
About Southern Star Energy.
Southern Star Energy has approximately 5500 acres under lease within the prospect area, which is defined by a string of ten vintage wells drilled in the 1950?s. The prospect area was historically developed on 640 acre spacing (wells approximately one mile apart). Most of these old wells were abandoned before 1972 after only producing from one relatively thin (20 feet) zone of the Cotton Valley sand members. None of the zones with identified reserve potential have been produced within a five mile radius of the prospect area. Preliminary plans, with continued successful evaluation drilling, will be to develop the leased acreage with at least one well per 160 acres. Analog fields are being economically developed with at least one well per 80 acres indicating that many more wells can be reasonably contemplated.
Information Regarding Forward-Looking Statements:
Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions in the Private Securities Legislation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Southern Star Energy?s actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things: volatility of natural resource prices; product demand; market competition and risks inherent in Southern Star Energy?s operations.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
HOUSTON--(BUSINESS WIRE)--Southern Star Energy Inc., (OTC BB: SSEY.OB) is pleased to provide an update the company?s well the R.C. Atkins 8-1.R.C. Atkins 8-1: Drilled and completed February 24, 2007 to depth of 9950 feet. First stage completion with perforations from 9084? thru 9291? was perforated and frac stimulated with a conventional ball out procedure from September 25 through September 27. The well was allowed to flow back and clean up to tanks until October 19 when operations commenced to complete the Upper Cotton Valley section from 8500? to 8876?. The Upper Cotton Valley section from 8500? through 8876? was completed utilizing the new coiled tubing conveyed minifrac method in six stages from October 19 through October 25. The well was allowed to flow back completion fluids up 4.5 inch casing and clean up over the next eight days (November 1) at which time it began to show traces of hydrocarbons. From November 1 through November 10, gas rates flowing up casing have built up to about 740 mcfpd and 25 bwph with flowing casing pressure of 575 psi. Production has stabilized at 505 mcfpd 30 bwph at flowing casing pressure of 575 psi on 24/64 choke. From November 12 through 14, a completion rig was set up running production tubing into the well. Also a 150 foot sales line has been installed to begin producing the well to sales.
All of the estimated recoverable oil and gas reserves in different zones are confirmed by mudlog, wireline logs evaluations and in some cases with sidewall cores and Formation Tester pressure measurement. Total of 64 feet estimated gas pay is distributed over a gross (total) interval of 900 feet in the Cotton Valley section. Three shallower zones demonstrating primarily oil potential will continue to be evaluated in subsequent wells. Results of those evaluations will determine the feasibility of additional future developments targeting the oil potential. The zones indicating oil potential are regionally known and have been economically developed within a ten mile radius of this well.
Further Information
Shareholders and prospective investors are encouraged to visit Southern Star Energy?s website: www.ssenergyinc.com to learn more about the Company and the Cotton Valley Trend. Please feel free to call investor relations at 1-800-733-2447 ext. 107 to receive a full corporate investor package.
About Southern Star Energy.
Southern Star Energy has approximately 5500 acres under lease within the prospect area, which is defined by a string of ten vintage wells drilled in the 1950?s. The prospect area was historically developed on 640 acre spacing (wells approximately one mile apart). Most of these old wells were abandoned before 1972 after only producing from one relatively thin (20 feet) zone of the Cotton Valley sand members. None of the zones with identified reserve potential have been produced within a five mile radius of the prospect area. Preliminary plans, with continued successful evaluation drilling, will be to develop the leased acreage with at least one well per 160 acres. Analog fields are being economically developed with at least one well per 80 acres indicating that many more wells can be reasonably contemplated.
Information Regarding Forward-Looking Statements:
Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions in the Private Securities Legislation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Southern Star Energy?s actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things: volatility of natural resource prices; product demand; market competition and risks inherent in Southern Star Energy?s operations.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
New Design Cabinets, Inc. Completes a $10 Million Financing and Closes a Merger with Stratos del Peru S.A.C.
Monday November 19, 9:00 am ET
LOS ANGELES & LIMA, Peru--(BUSINESS WIRE)--New Design Cabinets, Inc. (OTC BB: NDCB.OB) is pleased to announce that it has closed a Share Exchange Agreement with Stratos del Peru S.A.C. ("Stratos") and its shareholders (the ?Share Exchange Agreement?), and has completed a financing of approximately $10 million. The Company intends to change its name to ?Stratos Renewables Corporation? and change its ticker symbol by mid-December.
Stratos? goal is to be the leading Peruvian sugarcane ethanol company with planned production capacity of 154 million gallons per year. Ethanol is a clean burning, high octane fuel that is produced from renewable sources. Blending up to 20% ethanol into a gasoline supply can cut down on not only the amount of imported oil consumed, but also on the emissions generated by the burning of that fuel.
The Company intends for this financing to allow for the completion of the expansion of Stratos? current sugar mill, Estrella del Norte, in Northern Peru, to repay debt, and complete feasibility studies. The Company intends to proceed with plans to expand Stratos? sugar milling capacity to 700 tons of cane per day (tcd), and add an ethanol distillery capable of an additional 4 million gallons per year of ethanol production.
About the Company and Stratos del Peru S.A.C.
Stratos Renewables is committed to becoming a leader in Latin America's rapidly emerging sugarcane ethanol industry, a growing segment of the larger renewable fuel industry. The company believes Peru's economic growth and expansion, illustrated by recent exponential growth in foreign direct investment, and GDP growth over the last five years, adds to Peru's promise as an attractive geographical location for the cultivation, processing, distribution and use of alternative fuels. In addition, rating agency DBRS has recently assigned investment-grade credit ratings to Peru's long-term foreign and local currency debt. For more information about Stratos Renewables, please visit: www.stratosrenewablesenergy.com.
About Ethanol
Ethanol is a clean burning, high octane biofuel produced from grain, which is a renewable source, and can be grown year after year. In its most basic sense, ethanol is a grain alcohol produced from sources such as corn and sugar. Pure 100% ethanol is normally not used as a replacement for gasoline, but the integration of up to 20% ethanol into a gasoline supply can cut down on not only the amount of oil consumed, but also on the emissions generated by the burning of that fuel. Ethanol significantly reduces harmful exhaust emissions, which contribute to global warming. The United Nations expects all biofuels to account for a full 25% of world energy needs by 2025.
Notice Regarding Forward-Looking Statements
This news release contains ?forward-looking statements,? as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Since the forward-looking statements relate to future developments, results or events, these statements are highly speculative and involve risks, uncertainties and assumptions that are difficult to assess. You should not construe any of these statements as a definitive or invariable expression of what will actually occur or result. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release and the Company and Stratos assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time to time with the Securities and Exchange Commission and available at www.sec.gov.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
LOS ANGELES & LIMA, Peru--(BUSINESS WIRE)--New Design Cabinets, Inc. (OTC BB: NDCB.OB) is pleased to announce that it has closed a Share Exchange Agreement with Stratos del Peru S.A.C. ("Stratos") and its shareholders (the ?Share Exchange Agreement?), and has completed a financing of approximately $10 million. The Company intends to change its name to ?Stratos Renewables Corporation? and change its ticker symbol by mid-December.
Stratos? goal is to be the leading Peruvian sugarcane ethanol company with planned production capacity of 154 million gallons per year. Ethanol is a clean burning, high octane fuel that is produced from renewable sources. Blending up to 20% ethanol into a gasoline supply can cut down on not only the amount of imported oil consumed, but also on the emissions generated by the burning of that fuel.
The Company intends for this financing to allow for the completion of the expansion of Stratos? current sugar mill, Estrella del Norte, in Northern Peru, to repay debt, and complete feasibility studies. The Company intends to proceed with plans to expand Stratos? sugar milling capacity to 700 tons of cane per day (tcd), and add an ethanol distillery capable of an additional 4 million gallons per year of ethanol production.
About the Company and Stratos del Peru S.A.C.
Stratos Renewables is committed to becoming a leader in Latin America's rapidly emerging sugarcane ethanol industry, a growing segment of the larger renewable fuel industry. The company believes Peru's economic growth and expansion, illustrated by recent exponential growth in foreign direct investment, and GDP growth over the last five years, adds to Peru's promise as an attractive geographical location for the cultivation, processing, distribution and use of alternative fuels. In addition, rating agency DBRS has recently assigned investment-grade credit ratings to Peru's long-term foreign and local currency debt. For more information about Stratos Renewables, please visit: www.stratosrenewablesenergy.com.
About Ethanol
Ethanol is a clean burning, high octane biofuel produced from grain, which is a renewable source, and can be grown year after year. In its most basic sense, ethanol is a grain alcohol produced from sources such as corn and sugar. Pure 100% ethanol is normally not used as a replacement for gasoline, but the integration of up to 20% ethanol into a gasoline supply can cut down on not only the amount of oil consumed, but also on the emissions generated by the burning of that fuel. Ethanol significantly reduces harmful exhaust emissions, which contribute to global warming. The United Nations expects all biofuels to account for a full 25% of world energy needs by 2025.
Notice Regarding Forward-Looking Statements
This news release contains ?forward-looking statements,? as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Since the forward-looking statements relate to future developments, results or events, these statements are highly speculative and involve risks, uncertainties and assumptions that are difficult to assess. You should not construe any of these statements as a definitive or invariable expression of what will actually occur or result. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release and the Company and Stratos assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time to time with the Securities and Exchange Commission and available at www.sec.gov.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
BioForce Nanosciences Receives $500,000 From Investor Warrant Exercise
Monday November 19, 8:38 am ET
AMES, Iowa, Nov. 19, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings Inc. (OTC BB: BFNH.OB) today announced the receipt of $500,000 in proceeds from the exercise of the Series C warrants issued in its August 2007 financing transaction with an institutional investor. The Series C warrants entitled the investor to purchase 1,000,000 shares of BioForce's common stock at a price of $0.50 per share. These warrant exercise proceeds are in addition to the $500,000 of initial investment proceeds received in August.
BioForce's Chief Executive Officer, Dr. Eric Henderson, said, ``We appreciate this expression of continued support from the investor. The warrant exercise proceeds provide us with the funds necessary to continue expansion of our sales and marketing efforts related to our Nano eNabler system, a device for the deposition and nanoscale manipulation of biomolecules. The Nano eNabler is being utilized by over twenty preeminent research institutions, such as Harvard Medical School and Johns Hopkins University, enabling them to make breakthrough advances in cell biology, nanobiosensors and tissue engineering. These funds will also allow us to continue development of our ViriChip virus detection system, which can be used to detect multiple infectious viruses in a sample as small as a single drop of water.''
Greg Brown, BioForce's Chief Financial Officer, commented, ``The August 2007 transaction and this warrant exercise by the investor are a part of our strategy to continue to strengthen our balance sheet and insure that we have the working capital necessary to fund our growth. The recently announced $150,000 loan forgiveness by the State of Iowa is another part of this financial strategy, and we expect further developments in this area over the coming months.''
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization, patterning and cell adhesion, and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
AMES, Iowa, Nov. 19, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings Inc. (OTC BB: BFNH.OB) today announced the receipt of $500,000 in proceeds from the exercise of the Series C warrants issued in its August 2007 financing transaction with an institutional investor. The Series C warrants entitled the investor to purchase 1,000,000 shares of BioForce's common stock at a price of $0.50 per share. These warrant exercise proceeds are in addition to the $500,000 of initial investment proceeds received in August.
BioForce's Chief Executive Officer, Dr. Eric Henderson, said, ``We appreciate this expression of continued support from the investor. The warrant exercise proceeds provide us with the funds necessary to continue expansion of our sales and marketing efforts related to our Nano eNabler system, a device for the deposition and nanoscale manipulation of biomolecules. The Nano eNabler is being utilized by over twenty preeminent research institutions, such as Harvard Medical School and Johns Hopkins University, enabling them to make breakthrough advances in cell biology, nanobiosensors and tissue engineering. These funds will also allow us to continue development of our ViriChip virus detection system, which can be used to detect multiple infectious viruses in a sample as small as a single drop of water.''
Greg Brown, BioForce's Chief Financial Officer, commented, ``The August 2007 transaction and this warrant exercise by the investor are a part of our strategy to continue to strengthen our balance sheet and insure that we have the working capital necessary to fund our growth. The recently announced $150,000 loan forgiveness by the State of Iowa is another part of this financial strategy, and we expect further developments in this area over the coming months.''
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization, patterning and cell adhesion, and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
GeoPharma, Inc. Announces Marketing and Distribution Agreement With Vetoquinol
Monday November 19, 7:55 am ET
LARGO, Fla., Nov. 19 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (NasdaqCM: GORX) GeoPharma, Inc. reached an agreement with Vetoquinol USA (http://www.vetoquinolusa.com/index1.html) for the marketing and distribution of Vetprofen(TM) nationwide. The agreement executed with GeoPharma's wholly-owned subsidiary Belcher Pharmaceuticals represents GeoPharma's first generic drug offering and features the active ingredient Carprofen. Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians for the relief of pain and inflammation associated with osteoarthritis and post operative pain management in canines.
"Vetoquinol has long been a leader in the marketing and distribution of veterinary health products, so working with them was a logical choice to proliferate the acceptance of Vetprofen(TM) into the marketplace," said GeoPharma CEO Mihir K. Taneja.
"Vetoquinol is very pleased to be partnering with Belcher Pharmaceuticals in an effort to market and distribute Vetprofen(TM) (Carprofen) in the United States," stated Dan Schildgen, Director of Business Development for Vetoquinol USA. "This is an important opportunity for GeoPharma. Vetprofen as a companion animal pain management product is a very good fit for Vetoquinol's business model, in terms of species, geographic region and therapeutic segment. The introduction of Vetprofen will enhance Vetoquinol's presence in the U.S. market and complement its growing line of successful products."
About Vetoquinol:
Founded in 1933, Vetoquinol is the 12th largest animal health company worldwide dedicated to both livestock and companion animals. The company distributes products in approximately 100 different countries and employs over 1200 people. Vetoquinol is publicly traded on the Euronext Exchange in Paris, France. Vetoquinol acquired Evsco Pharmaceuticals and Tomlyn Products to form Vetoquinol USA. Additionally in December of 2006 Vetoquinol acquired VET Solutions (http://www.vetsolutions.com/).
Vetoquinol's business activities include research, manufacture, marketing and sales of medicines and nutraceuticals. Vetoquinol has developed expertise in 3 main areas: anti-infective, anti-inflammatory and cardio-nephrology. Leading products include Marbocyl® (anti-infective), Aurizon® (anti- infective), Prilium® (cardiology) and Tolfedine® (anti-inflammatory). Other successful offerings from Vetoquinol include Azodyl, Epakitin, Zentonil, Viralys/Enisyl-F, Nutrical, Fecalyzer, and Sebozole.
About GeoPharma Inc: GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the- counter, nutritional, generic drug and functional food products, as well as, health and beauty products for companies worldwide. This is accomplished by utilizing our wholly owned subsidiaries Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc. and Breakthrough Engineered Nutrition, Inc. Innovative Health Products and Libi Labs specialize in the development and manufacture of a broad range of nutritional supplements and cosmeceuticals. As a contract manufacturer, we develop and manufacture dietary supplements as well as health and beauty care products for distribution through various outlets. Belcher Pharmaceuticals, Inc is a state-of-the-art FDA-registered, drug development and manufacturing facility for generic and over-the-counter ("OTC") drugs. Breakthrough Engineered Nutrition, Inc. develops markets and distributes its own branded dietary supplements. Currently, DEX-L10, DEX-C20, OxyFirm and Cortiloss are among Breakthrough's top selling dietary products. Breakthrough's products are distributed nationwide and internationally in specialty, food, drug and mass outlets, including Target, Wal-Mart, GNC, Walgreens, CVS, Rite Aid, Duane Reade and many others. We also have an established network of brokers and distributors strategically located across the United States and Canada. GeoPharma's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com, www.hoodiadexL10.com, and www.onlineihp.com
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
LARGO, Fla., Nov. 19 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (NasdaqCM: GORX) GeoPharma, Inc. reached an agreement with Vetoquinol USA (http://www.vetoquinolusa.com/index1.html) for the marketing and distribution of Vetprofen(TM) nationwide. The agreement executed with GeoPharma's wholly-owned subsidiary Belcher Pharmaceuticals represents GeoPharma's first generic drug offering and features the active ingredient Carprofen. Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians for the relief of pain and inflammation associated with osteoarthritis and post operative pain management in canines.
"Vetoquinol has long been a leader in the marketing and distribution of veterinary health products, so working with them was a logical choice to proliferate the acceptance of Vetprofen(TM) into the marketplace," said GeoPharma CEO Mihir K. Taneja.
"Vetoquinol is very pleased to be partnering with Belcher Pharmaceuticals in an effort to market and distribute Vetprofen(TM) (Carprofen) in the United States," stated Dan Schildgen, Director of Business Development for Vetoquinol USA. "This is an important opportunity for GeoPharma. Vetprofen as a companion animal pain management product is a very good fit for Vetoquinol's business model, in terms of species, geographic region and therapeutic segment. The introduction of Vetprofen will enhance Vetoquinol's presence in the U.S. market and complement its growing line of successful products."
About Vetoquinol:
Founded in 1933, Vetoquinol is the 12th largest animal health company worldwide dedicated to both livestock and companion animals. The company distributes products in approximately 100 different countries and employs over 1200 people. Vetoquinol is publicly traded on the Euronext Exchange in Paris, France. Vetoquinol acquired Evsco Pharmaceuticals and Tomlyn Products to form Vetoquinol USA. Additionally in December of 2006 Vetoquinol acquired VET Solutions (http://www.vetsolutions.com/).
Vetoquinol's business activities include research, manufacture, marketing and sales of medicines and nutraceuticals. Vetoquinol has developed expertise in 3 main areas: anti-infective, anti-inflammatory and cardio-nephrology. Leading products include Marbocyl® (anti-infective), Aurizon® (anti- infective), Prilium® (cardiology) and Tolfedine® (anti-inflammatory). Other successful offerings from Vetoquinol include Azodyl, Epakitin, Zentonil, Viralys/Enisyl-F, Nutrical, Fecalyzer, and Sebozole.
About GeoPharma Inc: GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the- counter, nutritional, generic drug and functional food products, as well as, health and beauty products for companies worldwide. This is accomplished by utilizing our wholly owned subsidiaries Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc. and Breakthrough Engineered Nutrition, Inc. Innovative Health Products and Libi Labs specialize in the development and manufacture of a broad range of nutritional supplements and cosmeceuticals. As a contract manufacturer, we develop and manufacture dietary supplements as well as health and beauty care products for distribution through various outlets. Belcher Pharmaceuticals, Inc is a state-of-the-art FDA-registered, drug development and manufacturing facility for generic and over-the-counter ("OTC") drugs. Breakthrough Engineered Nutrition, Inc. develops markets and distributes its own branded dietary supplements. Currently, DEX-L10, DEX-C20, OxyFirm and Cortiloss are among Breakthrough's top selling dietary products. Breakthrough's products are distributed nationwide and internationally in specialty, food, drug and mass outlets, including Target, Wal-Mart, GNC, Walgreens, CVS, Rite Aid, Duane Reade and many others. We also have an established network of brokers and distributors strategically located across the United States and Canada. GeoPharma's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com, www.hoodiadexL10.com, and www.onlineihp.com
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Gulf Western Petroleum Announces Sales Line Hook up and 2nd Test Result in Brushy Creek V Project: Goodrich Delaplain # 1 Gas Unit Test at 259 MCFD
Thursday November 15, 2:00 am ET
HOUSTON, TX, Nov. 15 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC/Frankfurt: GER), is pleased to announce that the Goodrich-Delaplain # 1 four point flow test has been completed and the results are 259 Mcf gas per day with a FTP (Flowing Tubing Pressure) of 1410 psi. on a 5/64" choke. The Goodrich-Delaplain # 1 will initially be produced from a 15 foot sand section from 3350'-3365' the well was perforated from 3355' to 3360" and is now flowing into the sales line.
The Goodrich-Delaplain # 1 Gas Unit is part of the Brushy Creek V Natural Gas Project located in Lavaca County, Texas. The Brushy Creek V Project is a two well project generated by utilizing newly acquired 3D seismic data. The Pope # 1, the first well reported in this project, tested at 254 Mcfd was also hooked into the sales line November 14th.
President, Sam Nastat stated, "Brushy Creek V is now successfully completed and we are anticipating results from Phases IV and VI within the next few days. The five well Shamrock Project in Dewitt County is now completed with five out of five successful wells."
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
HOUSTON, TX, Nov. 15 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC/Frankfurt: GER), is pleased to announce that the Goodrich-Delaplain # 1 four point flow test has been completed and the results are 259 Mcf gas per day with a FTP (Flowing Tubing Pressure) of 1410 psi. on a 5/64" choke. The Goodrich-Delaplain # 1 will initially be produced from a 15 foot sand section from 3350'-3365' the well was perforated from 3355' to 3360" and is now flowing into the sales line.
The Goodrich-Delaplain # 1 Gas Unit is part of the Brushy Creek V Natural Gas Project located in Lavaca County, Texas. The Brushy Creek V Project is a two well project generated by utilizing newly acquired 3D seismic data. The Pope # 1, the first well reported in this project, tested at 254 Mcfd was also hooked into the sales line November 14th.
President, Sam Nastat stated, "Brushy Creek V is now successfully completed and we are anticipating results from Phases IV and VI within the next few days. The five well Shamrock Project in Dewitt County is now completed with five out of five successful wells."
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Perfisans Recieves a Big Order From China Cell Phone Company
Perfisans releases the business summary of Tiffany Technology Limited
Toronto, Ontario, CANADA, Nov. 15, 2007 –(PRIME NEWSWIRE)-- Perfisans Holdings Inc. (OTC BB: PFHD), a next-generation semiconductor design house focused on the high-speed wireless communication and consumer semiconductor markets, today announced that it has updated the merger with Tiffany Technology Ltd. with the release of the business summary for the company.
After signing the MOU to merge with Tiffany Technology Limited, a major channel distributor focused on consumer semiconductor components and supply for the growing demand within Chinese markets, Perfisans set up a Shenzhen office to provide local support.
In addition, Perfisans recently announced change of the company name to Aspire International Inc. to reflect the new globalization business plan of the company.
Tiffany Technology currently participates in the market of semiconductor component distribution sales for mobile phones, PDA, MP3, GPS and various handheld products, with the focus in the Chinese market first, and has the vision to go global.
The world market for semiconductor chips was estimated at $274 billion in 2006, and is expected to grow at a compound annual growth rate (CAGR) of 7.5% to $356 billion by 2011. China Mobile added a record 14 million users in the fourth quarter 2006, according to March 2007 reports from Bloomberg & China Digital Times.net. The latest statistics from China's Ministry of Information Industry shows that by the end of July 2007, there were more than 880 million telephone users in China, including 372 million fixed-line phone users and 508 million mobile phone users.
About Perfisans Holdings, Inc.
Founded in 2001, Perfisans Holdings, Inc. (http://www.perfisans.com/) is headquartered in the high-tech zone of Markham, Ontario, Canada, where companies such as AMD (www.amd.com), IBM (www.ibm.com), and Motorola (www.motorola.com) are located.
Perfisans is a fabless semiconductor company focused on developing leading edge, cost-effective, system-on-chip (SOC) integrated circuits (IC) and delivering innovative solutions that address the performance needs of next generation network interface systems. Rapidly being recognized and endorsed by industry leaders for its innovative ASIC architectures, the Company's technologies have applications in data-telecommunication, storage networks, content delivery networks, broadband networks, rich streaming media, broadband wireless and wireless surveillance applications.
Commercial and private network systems that utilize Perfisans’ products reward their operators with significantly faster network data throughput speeds, increased day-to-day operating efficiencies and enhanced bottom line performance. Enterprise operators welcome Perfisans’ full standards compliance and backward compatibility, which makes significant systems performance upgrades to existing network systems possible, and at very low cost. By avoiding the necessity for operators to buy expensive additional equipment, Perfisans’ technology allows its’ users to streamline cost, ultimately affecting their bottom line.
More information can be obtained from the Company's web site at http://www.perfisans.com/.
About Tiffany Technology Limited
Tiffany Technology Ltd. was founded by Tiffany Kwok on August 2005 with headquarters in Hong Kong. Tiffany Technology Ltd. is an electronics semiconductor component channel company that focuses on sales and marketing and delivers high quality services to the customers in mainland China and Asia Pacific region.
The Company’s mission is to provide superior services, fast turn around time, fast shipment, and a rich portfolio of products to the manufacturers.
More information can be obtained from the Company's web site at http://www.tiffanytech.com/
Cautionary Statement
This press release contains statements relating to future results of Perfisans (including certain projections and business trends) that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: the cyclical nature of the semiconductor industry and the markets addressed by the company's and its customers' products; demand for and market acceptance of new and existing products; successful development of new products; the timing of new product introductions; changes in product mix; product obsolescence; the availability of manufacturing capacity; fluctuations in manufacturing yields; pricing pressures and other competitive factors; the ability to develop and implement new technologies and to obtain protection for the related intellectual property; the uncertainties of litigation; our ability to attract and retain qualified personnel; as well as other risks and uncertainties, including those detailed from time to time in Perfisans' Securities and Exchange Commission filings. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Perfisans Holdings Limited
Investor Relations
(905) 943-9996, ext. 230
ir@perfisans.com
OR
RedChip Companies
Dave Gentry
(800) REDCHIP (733-2447), ext. 104
dave@redchip.com
Toronto, Ontario, CANADA, Nov. 15, 2007 –(PRIME NEWSWIRE)-- Perfisans Holdings Inc. (OTC BB: PFHD), a next-generation semiconductor design house focused on the high-speed wireless communication and consumer semiconductor markets, today announced that it has updated the merger with Tiffany Technology Ltd. with the release of the business summary for the company.
After signing the MOU to merge with Tiffany Technology Limited, a major channel distributor focused on consumer semiconductor components and supply for the growing demand within Chinese markets, Perfisans set up a Shenzhen office to provide local support.
In addition, Perfisans recently announced change of the company name to Aspire International Inc. to reflect the new globalization business plan of the company.
Tiffany Technology currently participates in the market of semiconductor component distribution sales for mobile phones, PDA, MP3, GPS and various handheld products, with the focus in the Chinese market first, and has the vision to go global.
The world market for semiconductor chips was estimated at $274 billion in 2006, and is expected to grow at a compound annual growth rate (CAGR) of 7.5% to $356 billion by 2011. China Mobile added a record 14 million users in the fourth quarter 2006, according to March 2007 reports from Bloomberg & China Digital Times.net. The latest statistics from China's Ministry of Information Industry shows that by the end of July 2007, there were more than 880 million telephone users in China, including 372 million fixed-line phone users and 508 million mobile phone users.
About Perfisans Holdings, Inc.
Founded in 2001, Perfisans Holdings, Inc. (http://www.perfisans.com/) is headquartered in the high-tech zone of Markham, Ontario, Canada, where companies such as AMD (www.amd.com), IBM (www.ibm.com), and Motorola (www.motorola.com) are located.
Perfisans is a fabless semiconductor company focused on developing leading edge, cost-effective, system-on-chip (SOC) integrated circuits (IC) and delivering innovative solutions that address the performance needs of next generation network interface systems. Rapidly being recognized and endorsed by industry leaders for its innovative ASIC architectures, the Company's technologies have applications in data-telecommunication, storage networks, content delivery networks, broadband networks, rich streaming media, broadband wireless and wireless surveillance applications.
Commercial and private network systems that utilize Perfisans’ products reward their operators with significantly faster network data throughput speeds, increased day-to-day operating efficiencies and enhanced bottom line performance. Enterprise operators welcome Perfisans’ full standards compliance and backward compatibility, which makes significant systems performance upgrades to existing network systems possible, and at very low cost. By avoiding the necessity for operators to buy expensive additional equipment, Perfisans’ technology allows its’ users to streamline cost, ultimately affecting their bottom line.
More information can be obtained from the Company's web site at http://www.perfisans.com/.
About Tiffany Technology Limited
Tiffany Technology Ltd. was founded by Tiffany Kwok on August 2005 with headquarters in Hong Kong. Tiffany Technology Ltd. is an electronics semiconductor component channel company that focuses on sales and marketing and delivers high quality services to the customers in mainland China and Asia Pacific region.
The Company’s mission is to provide superior services, fast turn around time, fast shipment, and a rich portfolio of products to the manufacturers.
More information can be obtained from the Company's web site at http://www.tiffanytech.com/
Cautionary Statement
This press release contains statements relating to future results of Perfisans (including certain projections and business trends) that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: the cyclical nature of the semiconductor industry and the markets addressed by the company's and its customers' products; demand for and market acceptance of new and existing products; successful development of new products; the timing of new product introductions; changes in product mix; product obsolescence; the availability of manufacturing capacity; fluctuations in manufacturing yields; pricing pressures and other competitive factors; the ability to develop and implement new technologies and to obtain protection for the related intellectual property; the uncertainties of litigation; our ability to attract and retain qualified personnel; as well as other risks and uncertainties, including those detailed from time to time in Perfisans' Securities and Exchange Commission filings. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Perfisans Holdings Limited
Investor Relations
(905) 943-9996, ext. 230
ir@perfisans.com
OR
RedChip Companies
Dave Gentry
(800) REDCHIP (733-2447), ext. 104
dave@redchip.com
BioForce Nanosciences Reports Third Quarter 2007 Financial Results
AMES, Iowa, Nov. 15, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH) reported yesterday that its total revenue for the three months ended September 30, 2007 was $35,842, a 14% increase over the revenue of $31,430 for the same period in 2006. For the nine months ended September 30, 2007, revenue was $579,408, a 121% increase as compared to the revenue of $261,628 for the nine months ended September 30, 2006.
Net loss for the third quarter of 2007 was $1,268,845, as compared to a net loss of $773,457 for the same period in 2006. Net loss for the nine months ended September 30, 2007 was $3,277,720, as compared to a net loss of $2,810,824 for the nine months ended September 30, 2006.
Net loss on common stock for the quarter was $1,403,289, or $0.06 per share, as compared to $773,457, or $0.03 per share, for the same period in 2006. Net loss on common stock for the nine months ended September 30, 2007 was $3,412,164, or $0.14 per share, as compared to $2,810,824, or $0.12 per share, for the nine months ended September 30, 2006. The difference between net loss for the three and nine month periods ended September 30, 2007 and the net loss on common stock for those periods is almost entirely attributable to an amount recorded as a preferred stock conversion discount in association with the company's August 2007 equity financing transaction.
Dr. Eric Henderson, BioForce's CEO and founder, said, "Marketplace momentum associated with the 2006 market launch of the Nano eNabler system continues to progress well. While no Nano eNabler system sales were recorded during the third quarter, there have been two Nano eNabler sales thus far during the fourth quarter of 2007, including the recently announced sale to the University of Wales, and we anticipate additional Nano eNabler sales before the end of the year. More than twenty premier research institutions throughout the world are now using Nano eNablers, with the system's ability to deposit and manipulate biomaterials with nanoscale precision allowing these researchers to make breakthrough advances in areas like cell biology, nanobiosensors and tissue engineering."
Dr. Henderson continued, "In addition to the commercial progress being made with the Nano eNabler, we continue to utilize the Nano eNabler ourselves in order to pursue development of our ViriChip virus detection system, Chip-on-a-Tip biomarker diagnostic test platform and other innovative diagnostic tests. These diagnostic tests have application in the areas of healthcare, biodefense and environmental protection, and represent a significant part of the company's growth strategy. For example, using the ViriChip technology we can design a test to detect multiple infectious viruses in a single drop of water."
Greg Brown, BioForce's CFO, commented, "During the third quarter of 2007 we were able to strengthen our balance sheet via the completion of our August 2007 equity financing. We were very pleased to be able to secure that funding on the basis of fixed rather than variable pricing, ensuring that the investor's interests are in fact completely aligned with those of our other shareholders. In addition, the recently announced $150,000 loan forgiveness by the State of Iowa further strengthens our balance sheet."
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization, patterning and cell adhesion, and printing proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
CLICK HERE TO VIEW FILINGS
CONTACT: BioForce Nanosciences Holdings, Inc.
Greg Brown, CFO
515-233-8333 ext. 118
gbrown@bioforcenano.com
RedChip Companies, Inc.
Investor Relations
Dave Gentry
1-800-REDCHIP (733-2447) ext. 104
dave@redchip.com
www.redchip.com
Net loss for the third quarter of 2007 was $1,268,845, as compared to a net loss of $773,457 for the same period in 2006. Net loss for the nine months ended September 30, 2007 was $3,277,720, as compared to a net loss of $2,810,824 for the nine months ended September 30, 2006.
Net loss on common stock for the quarter was $1,403,289, or $0.06 per share, as compared to $773,457, or $0.03 per share, for the same period in 2006. Net loss on common stock for the nine months ended September 30, 2007 was $3,412,164, or $0.14 per share, as compared to $2,810,824, or $0.12 per share, for the nine months ended September 30, 2006. The difference between net loss for the three and nine month periods ended September 30, 2007 and the net loss on common stock for those periods is almost entirely attributable to an amount recorded as a preferred stock conversion discount in association with the company's August 2007 equity financing transaction.
Dr. Eric Henderson, BioForce's CEO and founder, said, "Marketplace momentum associated with the 2006 market launch of the Nano eNabler system continues to progress well. While no Nano eNabler system sales were recorded during the third quarter, there have been two Nano eNabler sales thus far during the fourth quarter of 2007, including the recently announced sale to the University of Wales, and we anticipate additional Nano eNabler sales before the end of the year. More than twenty premier research institutions throughout the world are now using Nano eNablers, with the system's ability to deposit and manipulate biomaterials with nanoscale precision allowing these researchers to make breakthrough advances in areas like cell biology, nanobiosensors and tissue engineering."
Dr. Henderson continued, "In addition to the commercial progress being made with the Nano eNabler, we continue to utilize the Nano eNabler ourselves in order to pursue development of our ViriChip virus detection system, Chip-on-a-Tip biomarker diagnostic test platform and other innovative diagnostic tests. These diagnostic tests have application in the areas of healthcare, biodefense and environmental protection, and represent a significant part of the company's growth strategy. For example, using the ViriChip technology we can design a test to detect multiple infectious viruses in a single drop of water."
Greg Brown, BioForce's CFO, commented, "During the third quarter of 2007 we were able to strengthen our balance sheet via the completion of our August 2007 equity financing. We were very pleased to be able to secure that funding on the basis of fixed rather than variable pricing, ensuring that the investor's interests are in fact completely aligned with those of our other shareholders. In addition, the recently announced $150,000 loan forgiveness by the State of Iowa further strengthens our balance sheet."
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization, patterning and cell adhesion, and printing proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
CLICK HERE TO VIEW FILINGS
CONTACT: BioForce Nanosciences Holdings, Inc.
Greg Brown, CFO
515-233-8333 ext. 118
gbrown@bioforcenano.com
RedChip Companies, Inc.
Investor Relations
Dave Gentry
1-800-REDCHIP (733-2447) ext. 104
dave@redchip.com
www.redchip.com
Tuesday, November 13, 2007
NZYM News Alert
Synthetech Reports Second Quarter Fiscal 2008 Results
Monday November 12, 4:09 pm ET
ALBANY, Ore., Nov. 12 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC BB: NZYM.OB) today announced financial results for the second quarter of fiscal 2008, which ended September 30, 2007. Revenue for the quarter was $3.0 million, a 6% decrease compared to revenue of $3.2 million in the second quarter of fiscal 2007. Operating loss for the current quarter was $841,000, compared to operating income of $203,000 for the same period last year. Net loss for the current quarter was $861,000, or $0.06 per share, compared to last year's second quarter net income of $198,000, or $0.01 per share.
For the first half of fiscal 2008, revenue of $7.2 million resulted in an operating loss of $705,000 and a net loss of $742,000, or $0.05 per share. For the comparable period last year, revenue of $4.9 million resulted in an operating loss of $592,000 and a net loss of $587,000, or $0.04 per share.
International sales, mainly to Europe, were $1.3 million and $3.3 million in the second quarter and first six months of fiscal 2008, respectively, compared to $780,000 and $1.6 million in the second quarter and first six months of fiscal 2007, respectively. International sales, like all of our revenues, are subject to significant quarterly fluctuations.
Financial results for the second quarter of fiscal 2008 were disappointing. A net loss of $861,000 for the second quarter of fiscal 2008 was a significantly larger loss than Synthetech normally would have expected on quarterly revenue of $3.0 million. Production process difficulties carried over from the first quarter combining to reduce revenue for the second quarter and increase the unit cost of the product produced. Based on a typical product mix, second quarter revenue of $3.0 million is inadequate to support Synthetech's cost structure which has been increasing over the past nine months in response to improving market conditions. During the quarter, Synthetech incurred $385,000 of unfavorable inventory adjustments, approximately $197,000 of this amount relate to inventory items in support of specific customer drug development projects which have been discontinued.
Research and development expense for the first six months of fiscal 2008 compared to the comparable period of fiscal 2007 increased $67,000 primarily due to the result of compensation and related costs pertaining to an increase in the number of chemists employed by Synthetech; general increases in salaries and benefits; and costs associated with hiring of new employees. These changes were made in response to improving business conditions and the need to provide competitive compensation packages.
Selling, general and administrative expense for the first six months of fiscal 2008 compared to the comparable period of fiscal 2007 increased $256,000 primarily as the result of an increase in stock-based compensation expense; the addition of a new senior sales position; general increases in salaries and benefits; and an increase in consulting fees related to the implementation of Section 404 of the Sarbanes-Oxley Act.
Click here to view filings
Commenting on the financial results, Dr. Gregory Hahn, President and COO, stated, "Synthetech's financial recovery encountered a setback during the second quarter of fiscal 2008. While softer quarterly sales had some impact, production issues were the major contributor to disappointing revenue and net income. We continue to focus significant resources on improving the reliability and performance of manufacturing resources. Synthetech's order backlog of approximately $3.4 million as of September 30, 2007 and additional orders received through November 12, 2007 suggest our markets remain reasonably robust, although order lead times remain short, limiting our visibility into the fourth quarter of fiscal 2008 and into fiscal 2009."
Dr. Daniel Fagan, Chairman and CEO stated, "We budgeted fiscal 2008 to be a mildly profitable rebuilding year in which Synthetech rebuilds its R&D and production capabilities for anticipated market demands in the future. Our financial recovery and strategic activity have been temporarily delayed because of the first and second quarter production difficulties which are in the process of being resolved. Many of these products have never been manufactured on large scale and may therefore pose production challenges until commercial processes are developed."
Management anticipates that Synthetech's revenue will continue to be volatile from period to period. Variability in Synthetech's level of revenue is based primarily on its participation in large-scale customer projects and the timing of shipments arising from these projects. Synthetech operates in a challenging business environment, characterized by the unpredictable dynamics and life cycle of pharmaceutical projects, which can lead to rapid fluctuations in the mix of projects and revenues. As the uncertainties inherent in drug development projects remain outside of Synthetech's control, it is difficult to predict the progress, timing and revenue potential of these projects.
About Synthetech
Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech's products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer's clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases.
Forward-Looking Statements
This press release contains "forward looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking, including, without limitation, statements regarding: future operating results; the timing and amount of shipments; recurrence of large-scale projects; resolution of manufacturing process difficulties; status of markets; and estimated quarterly stock-based compensation amounts for the remainder of fiscal 2008 and continued ongoing cost for implementing Section 404 of the Sarbanes-Oxley Act for the remainder of fiscal 2008. Words such as "believe," "anticipate," "expect," "estimate," "project," "will be," "will continue," "will likely result," or words or phrases of similar meanings identify forward-looking statements. Forward-looking statements reflect management's current expectations, plans or projections and are inherently uncertain and actual results could differ materially from such expectations, plans or projections. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Risks and uncertainties that could cause actual results to differ significantly from management's expectations include, but are not limited to, the following: Synthetech's limited financial and other resources; the uncertain market for Synthetech's products; potential loss of a significant customer; customer concentration; potential termination or suspension by customers of significant projects or orders; potential period-to-period revenue or expense fluctuations; production factors and timely access to raw materials; industry cost factors and conditions; competition; government regulation; labor disputes; technological changes; international business risks; and future incentive stock awards. Investors are urged to read Synthetech's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2007, for a further description of risks and uncertainties related to forward-looking statements made by Synthetech as well as to other aspects of Synthetech's business. Those reports describe, some, but not all of the factors that could cause actual results to differ significantly from management's expectations. Additional risks and uncertainties not presently known to Synthetech or which Synthetech currently deems immaterial also may impair its business or operations. Synthetech does not intend to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
MORE INFORMATION:
Web site: http://www.synthetech.com
E-mail: investor@synthetech.com
CONTACT: Gary Weber, CFO
PO Box 646
Albany, Oregon 97321
541 967-6575
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 12, 4:09 pm ET
ALBANY, Ore., Nov. 12 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC BB: NZYM.OB) today announced financial results for the second quarter of fiscal 2008, which ended September 30, 2007. Revenue for the quarter was $3.0 million, a 6% decrease compared to revenue of $3.2 million in the second quarter of fiscal 2007. Operating loss for the current quarter was $841,000, compared to operating income of $203,000 for the same period last year. Net loss for the current quarter was $861,000, or $0.06 per share, compared to last year's second quarter net income of $198,000, or $0.01 per share.
For the first half of fiscal 2008, revenue of $7.2 million resulted in an operating loss of $705,000 and a net loss of $742,000, or $0.05 per share. For the comparable period last year, revenue of $4.9 million resulted in an operating loss of $592,000 and a net loss of $587,000, or $0.04 per share.
International sales, mainly to Europe, were $1.3 million and $3.3 million in the second quarter and first six months of fiscal 2008, respectively, compared to $780,000 and $1.6 million in the second quarter and first six months of fiscal 2007, respectively. International sales, like all of our revenues, are subject to significant quarterly fluctuations.
Financial results for the second quarter of fiscal 2008 were disappointing. A net loss of $861,000 for the second quarter of fiscal 2008 was a significantly larger loss than Synthetech normally would have expected on quarterly revenue of $3.0 million. Production process difficulties carried over from the first quarter combining to reduce revenue for the second quarter and increase the unit cost of the product produced. Based on a typical product mix, second quarter revenue of $3.0 million is inadequate to support Synthetech's cost structure which has been increasing over the past nine months in response to improving market conditions. During the quarter, Synthetech incurred $385,000 of unfavorable inventory adjustments, approximately $197,000 of this amount relate to inventory items in support of specific customer drug development projects which have been discontinued.
Research and development expense for the first six months of fiscal 2008 compared to the comparable period of fiscal 2007 increased $67,000 primarily due to the result of compensation and related costs pertaining to an increase in the number of chemists employed by Synthetech; general increases in salaries and benefits; and costs associated with hiring of new employees. These changes were made in response to improving business conditions and the need to provide competitive compensation packages.
Selling, general and administrative expense for the first six months of fiscal 2008 compared to the comparable period of fiscal 2007 increased $256,000 primarily as the result of an increase in stock-based compensation expense; the addition of a new senior sales position; general increases in salaries and benefits; and an increase in consulting fees related to the implementation of Section 404 of the Sarbanes-Oxley Act.
Click here to view filings
Commenting on the financial results, Dr. Gregory Hahn, President and COO, stated, "Synthetech's financial recovery encountered a setback during the second quarter of fiscal 2008. While softer quarterly sales had some impact, production issues were the major contributor to disappointing revenue and net income. We continue to focus significant resources on improving the reliability and performance of manufacturing resources. Synthetech's order backlog of approximately $3.4 million as of September 30, 2007 and additional orders received through November 12, 2007 suggest our markets remain reasonably robust, although order lead times remain short, limiting our visibility into the fourth quarter of fiscal 2008 and into fiscal 2009."
Dr. Daniel Fagan, Chairman and CEO stated, "We budgeted fiscal 2008 to be a mildly profitable rebuilding year in which Synthetech rebuilds its R&D and production capabilities for anticipated market demands in the future. Our financial recovery and strategic activity have been temporarily delayed because of the first and second quarter production difficulties which are in the process of being resolved. Many of these products have never been manufactured on large scale and may therefore pose production challenges until commercial processes are developed."
Management anticipates that Synthetech's revenue will continue to be volatile from period to period. Variability in Synthetech's level of revenue is based primarily on its participation in large-scale customer projects and the timing of shipments arising from these projects. Synthetech operates in a challenging business environment, characterized by the unpredictable dynamics and life cycle of pharmaceutical projects, which can lead to rapid fluctuations in the mix of projects and revenues. As the uncertainties inherent in drug development projects remain outside of Synthetech's control, it is difficult to predict the progress, timing and revenue potential of these projects.
About Synthetech
Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech's products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer's clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases.
Forward-Looking Statements
This press release contains "forward looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking, including, without limitation, statements regarding: future operating results; the timing and amount of shipments; recurrence of large-scale projects; resolution of manufacturing process difficulties; status of markets; and estimated quarterly stock-based compensation amounts for the remainder of fiscal 2008 and continued ongoing cost for implementing Section 404 of the Sarbanes-Oxley Act for the remainder of fiscal 2008. Words such as "believe," "anticipate," "expect," "estimate," "project," "will be," "will continue," "will likely result," or words or phrases of similar meanings identify forward-looking statements. Forward-looking statements reflect management's current expectations, plans or projections and are inherently uncertain and actual results could differ materially from such expectations, plans or projections. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Risks and uncertainties that could cause actual results to differ significantly from management's expectations include, but are not limited to, the following: Synthetech's limited financial and other resources; the uncertain market for Synthetech's products; potential loss of a significant customer; customer concentration; potential termination or suspension by customers of significant projects or orders; potential period-to-period revenue or expense fluctuations; production factors and timely access to raw materials; industry cost factors and conditions; competition; government regulation; labor disputes; technological changes; international business risks; and future incentive stock awards. Investors are urged to read Synthetech's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2007, for a further description of risks and uncertainties related to forward-looking statements made by Synthetech as well as to other aspects of Synthetech's business. Those reports describe, some, but not all of the factors that could cause actual results to differ significantly from management's expectations. Additional risks and uncertainties not presently known to Synthetech or which Synthetech currently deems immaterial also may impair its business or operations. Synthetech does not intend to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
MORE INFORMATION:
Web site: http://www.synthetech.com
E-mail: investor@synthetech.com
CONTACT: Gary Weber, CFO
PO Box 646
Albany, Oregon 97321
541 967-6575
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday, November 12, 2007
ONSM News Alert
Onstream Media's Webcasting Division Achieves Record Monthly Revenue During October
Monday November 12, 2:14 pm ET
October Webcasting Revenue Reaches $648,000, a 66% Increase Over Prior Year
POMPANO BEACH, Fla., Nov. 12 /PRNewswire-FirstCall/ -- Onstream Media Corporation (NasdaqCM: ONSM), an online service provider of live and on-demand digital media, communications and applications, announced today that the Webcasting division of its Web Communications Services Group achieved record revenue of approximately $648,000 during October 2007. This represents an increase of approximately 66% over the approximately $390,000 in webcasting revenue recorded during the same month of the previous year (October 2006), and also represents the Company's highest single month of webcasting revenues level since its 1993 inception.
Randy Selman, President and Chief Executive Officer of Onstream Media, stated, "We are very pleased with the significant revenue growth being achieved by our Webcasting division, particularly as it solely reflects organic growth. We believe this achievement clearly demonstrates the quality and capability of our Visual Webcaster service and the increasing demand in the market for web based communications solutions. Looking ahead, anticipated enhancements to our webcasting platform, including Visual Webcaster HD(TM) and iEncode(TM), a full-featured, turnkey, standalone webcasting solution, plus the continuing expansion of our marketing efforts, will help us further expand our share of the growing market for webcasting and digital media services."
The Company also noted that while the record monthly revenue achieved in October does indicate the continued growth of its Webcasting division, results from one month should not be used to extrapolate and/or project revenues for the quarter ending December 31, 2007 or for any other monthly, quarterly or annual periods.
About Onstream Media:
Onstream Media Corporation (NasdaqCM: ONSM) is an online service provider of live and on-demand internet video, corporate web communications and content management applications. Onstream Media's pioneering Digital Media Services Platform (DMSP) provides customers with cost effective tools for encoding, managing, indexing, and publishing content via the Internet. The DMSP provides our clients with intelligent delivery and syndication of video advertising, and supports pay-per-view for online video and other rich media assets. The DMSP also provides an efficient workflow for transcoding and publishing user-generated content in combination with social networks and online video classifieds. In addition, Onstream Media provides live and on- demand webcasting, webinars, web and audio conferencing services. In fact, almost half of the Fortune 1000 companies and 78% of the Fortune 100 CEOs and CFOs have used Onstream Media's services.
Select Onstream Media customers include: AOL, AAA, AXA Equitable Life Insurance Company, Bonnier Corporation, Dell, Deutsche Bank, Disney, National Press Club, NHL, MGM, PR Newswire, Rodale, Inc., Televisa, WireOne, Shareholder.com (NASDAQ), and the U.S. Government. Onstream Media's strategic relationships include Akamai, Adobe, eBay, FiveAcross/Cisco and Qwest. For more information, visit Onstream Media at http://www.onstreammedia.com or call 954-917-6655.
Certain statements in this document and elsewhere by Onstream Media are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. economy; government policies and regulations, including, but not limited to those affecting the Internet. Onstream Media undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in Onstream Media Corporation's filings with the Securities and Exchange Commission.
Media Relations:
Beth Amorosi
FastLane Communications
973-582-3498
bamorosi@fast-lane.net
Investor Relations:
Brett Maas
Hayden Communications, Inc.
646-536-7331
brett@haydenir.com
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday November 12, 2:14 pm ET
October Webcasting Revenue Reaches $648,000, a 66% Increase Over Prior Year
POMPANO BEACH, Fla., Nov. 12 /PRNewswire-FirstCall/ -- Onstream Media Corporation (NasdaqCM: ONSM), an online service provider of live and on-demand digital media, communications and applications, announced today that the Webcasting division of its Web Communications Services Group achieved record revenue of approximately $648,000 during October 2007. This represents an increase of approximately 66% over the approximately $390,000 in webcasting revenue recorded during the same month of the previous year (October 2006), and also represents the Company's highest single month of webcasting revenues level since its 1993 inception.
Randy Selman, President and Chief Executive Officer of Onstream Media, stated, "We are very pleased with the significant revenue growth being achieved by our Webcasting division, particularly as it solely reflects organic growth. We believe this achievement clearly demonstrates the quality and capability of our Visual Webcaster service and the increasing demand in the market for web based communications solutions. Looking ahead, anticipated enhancements to our webcasting platform, including Visual Webcaster HD(TM) and iEncode(TM), a full-featured, turnkey, standalone webcasting solution, plus the continuing expansion of our marketing efforts, will help us further expand our share of the growing market for webcasting and digital media services."
The Company also noted that while the record monthly revenue achieved in October does indicate the continued growth of its Webcasting division, results from one month should not be used to extrapolate and/or project revenues for the quarter ending December 31, 2007 or for any other monthly, quarterly or annual periods.
About Onstream Media:
Onstream Media Corporation (NasdaqCM: ONSM) is an online service provider of live and on-demand internet video, corporate web communications and content management applications. Onstream Media's pioneering Digital Media Services Platform (DMSP) provides customers with cost effective tools for encoding, managing, indexing, and publishing content via the Internet. The DMSP provides our clients with intelligent delivery and syndication of video advertising, and supports pay-per-view for online video and other rich media assets. The DMSP also provides an efficient workflow for transcoding and publishing user-generated content in combination with social networks and online video classifieds. In addition, Onstream Media provides live and on- demand webcasting, webinars, web and audio conferencing services. In fact, almost half of the Fortune 1000 companies and 78% of the Fortune 100 CEOs and CFOs have used Onstream Media's services.
Select Onstream Media customers include: AOL, AAA, AXA Equitable Life Insurance Company, Bonnier Corporation, Dell, Deutsche Bank, Disney, National Press Club, NHL, MGM, PR Newswire, Rodale, Inc., Televisa, WireOne, Shareholder.com (NASDAQ), and the U.S. Government. Onstream Media's strategic relationships include Akamai, Adobe, eBay, FiveAcross/Cisco and Qwest. For more information, visit Onstream Media at http://www.onstreammedia.com or call 954-917-6655.
Certain statements in this document and elsewhere by Onstream Media are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. economy; government policies and regulations, including, but not limited to those affecting the Internet. Onstream Media undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in Onstream Media Corporation's filings with the Securities and Exchange Commission.
Media Relations:
Beth Amorosi
FastLane Communications
973-582-3498
bamorosi@fast-lane.net
Investor Relations:
Brett Maas
Hayden Communications, Inc.
646-536-7331
brett@haydenir.com
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Subscribe to:
Posts (Atom)
